var title_f42_58_43936="Patient information: Undescended testes (The Basics)";
var content_f42_58_43936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Undescended testes (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/undescended-testes-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H114719220\">",
"      <span class=\"h1\">",
"       What are undescended testes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The testes are the ball-shaped organs that hang between a boy&rsquo;s legs, inside a skin sac called the &ldquo;scrotum.&rdquo; Before a boy is born, his testes are inside the lower part of his belly.",
"     </p>",
"     <p>",
"      Just before birth, the testes move down into the scrotum. If this does not happen, doctors call the problem undescended testes, or &ldquo;cryptorchidism.&rdquo; It can happen to 1 or both testes.",
"     </p>",
"     <p>",
"      Sometimes, 1 or both testes do not develop normally because of a problem that happens before the baby is born. Doctors call this condition &ldquo;absent testis.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H114719235\">",
"      <span class=\"h1\">",
"       How can I tell if my baby has undescended testes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most of the time, the doctor finds the problem while doing an exam on the baby soon after birth. It is more common in babies who are born earlier than normal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H114719252\">",
"      <span class=\"h1\">",
"       How are undescended testes treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In most cases, no treatment is needed because the testes move down to the scrotum within a few months after birth. If that does not happen, treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Injections (shots) of a hormone called hCG",
"       </li>",
"       <li>",
"        Surgery to move the testicle or testicles into the scrotum",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These treatments can be started when the child is 6 months old. They should be done before a child is 2 years old.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H114719267\">",
"      <span class=\"h1\">",
"       Can undescended testes cause other problems?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Men who had undescended testes in childhood are more likely to have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cancer of the testes &ndash; Cancer of the testes is rare--even if a man had undescended testes. Still, the doctor or nurse will do exams to check for this at yearly physical exams.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Trouble getting a woman pregnant (called &ldquo;infertility&rdquo;) &ndash; This problem is more common in men who had 2 undescended testes. But most of these men are still able to get a woman pregnant.",
"       </li>",
"      </ul>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/58/43936?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83450 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43936=[""].join("\n");
var outline_f42_58_43936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114719220\">",
"      What are undescended testes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114719235\">",
"      How can I tell if my baby has undescended testes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114719252\">",
"      How are undescended testes treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114719267\">",
"      Can undescended testes cause other problems?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_58_43937="HCG in quiescent GTD";
var content_f42_58_43937=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Quiescent GTD cases consulting with USA hCG Reference Service",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Case",
"       </td>",
"       <td class=\"subtitle1\">",
"        hCG at referral, mIU/ml",
"       </td>",
"       <td class=\"subtitle1\">",
"        hCG-H, percent total hCG",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recurrence, percent hCG-H at detection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial gestational event",
"       </td>",
"       <td class=\"subtitle1\">",
"        Therapy received for persistent low hCG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 15",
"       </td>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        Taxol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 28",
"       </td>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 41",
"       </td>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 55",
"       </td>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        EMA-CO, EMA-EP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 20",
"       </td>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        Mtx, EMA-CO, Hys",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 63",
"       </td>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        161",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        212",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, BSO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        5.3",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        EMA-CO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        9.2",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, EMA-CO, Hys",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, ActD, EMA-CO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, ActD, EMA-CO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        EMA-EP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, ActD, Hys, BSO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Hys, BSO, ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 19",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        8.2",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 21",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 33",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 37",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 43",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 58",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx, ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 60",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 91",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 100",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 15",
"       </td>",
"       <td>",
"        Complete mole",
"       </td>",
"       <td>",
"        EMA-CO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        141",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        GTN",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        GTN",
"       </td>",
"       <td>",
"        Mtx, ActD, Hys, BSO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        GTN",
"       </td>",
"       <td>",
"        Mtx, ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        GTN",
"       </td>",
"       <td>",
"        Mtx, ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        GTN",
"       </td>",
"       <td>",
"        Hys, Mtx, EMA-CO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        GTN",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        GTN",
"       </td>",
"       <td>",
"        Hys",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        GTN",
"       </td>",
"       <td>",
"        EMA-CO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        GTN",
"       </td>",
"       <td>",
"        EMA-CO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        GTN",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 14",
"       </td>",
"       <td>",
"        GTN",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Partial mole",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Partial mole",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Partial mole",
"       </td>",
"       <td>",
"        EMA-CO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Partial mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Partial mole",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Partial mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Partial mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 29",
"       </td>",
"       <td>",
"        Partial mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 37",
"       </td>",
"       <td>",
"        Partial mole",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        Mtx, ActD, EMA-CO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        Hys, BSO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        10.7",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        Mtx, ActD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 14",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 23",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        Mtx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 57",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"       <td>",
"        Yes, 63",
"       </td>",
"       <td>",
"        SAB",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SAB: spontaneous abortion assumed to be partial hydatidiform mole; Mtx: methotrexate; ActD: actinomycin D; EMA-CO: etoposide, Mtc, ActD, Cyclophosphamide, Vincristine; EMA-EP: etoposide, Mtx, ActD, etoposide and cisplatinin; Hys: hysterectomy; BSO: bilateral salphingo-oophorectomy.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43937=[""].join("\n");
var outline_f42_58_43937=null;
var title_f42_58_43938="Bowel resection and reapprox C";
var content_f42_58_43938=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Anterior seromuscular imbricating layer during bowel resection and reanastomosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43938=[""].join("\n");
var outline_f42_58_43938=null;
var title_f42_58_43939="Anatomy occult SUI";
var content_f42_58_43939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F85778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F85778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Anatomy of occult stress urinary incontinence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Advanced anterior or apical pelvic organ prolapse (usually prolapse past the vaginal introitus) displaces the bladder neck posteriorly and the urethra is kinked, resulting in urethral obstruction. The obstruction then becomes the mechanism of continence.",
"    <br/>",
"    (B) When the prolapsed structures are elevated (approximating normal anatomy) during prolapse reduction testing in women with urethral obstruction due to advanced prolapse, the urethra is unblocked and stress urinary incontinence often becomes evident when a urinary stress test is performed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jasmine Tan-Kim, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43939=[""].join("\n");
var outline_f42_58_43939=null;
var title_f42_58_43940="Median nail dystrophy";
var content_f42_58_43940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Median nail dystrophy, also called median canaliform dystrophy of Heller",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43940=[""].join("\n");
var outline_f42_58_43940=null;
var title_f42_58_43941="General principles of fracture management: Bone healing and fracture description";
var content_f42_58_43941=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of fracture management: Bone healing and fracture description",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/58/43941/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/58/43941/contributors\">",
"     Anthony Beutler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/58/43941/contributors\">",
"     Mark B Stephens, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/58/43941/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/58/43941/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/58/43941/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/58/43941/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/58/43941/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Competent fracture care requires a basic knowledge of bone biology and healing, a systematic approach to fracture evaluation and description, and a practical understanding of basic splinting and casting techniques. The general principles of bone healing and proper fracture description will be reviewed here. Fractures that are complicated, high risk, or unresponsive to appropriate conservative management should be promptly referred to an orthopedic surgeon.",
"   </p>",
"   <p>",
"    For information on specific fractures, please see the relevant topic reviews. Stress fractures and pediatric fractures are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=see_link\">",
"     \"General principles of fracture management: Fracture patterns and description in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOLOGY OF BONE HEALING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone is a composite structure with mineral and organic components. The mineral component contains calcium, phosphate, and hydroxyl ions which are organized into a compound called hydroxyapatite (Ca5(PO4)3(OH)). This mineral skeleton provides the strength, stiffness, and rigidity characteristic of bone. The organic or protein component consists primarily of type I collagen, which lends tensile strength and resiliency. The outer covering of bone, the periosteum, provides the vascular supply that plays an essential role in fracture healing. The periosteum in children is substantially thicker and more robust than in adults, accounting in part for the more rapid healing of pediatric fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43941/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone healing is usually divided into three slightly overlapping stages: inflammatory, reparative, and remodeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43941/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. It is difficult to provide an approximate time frame for each phase because healing rates vary widely according to age and comorbidities. As an example, a simple toe fracture in a healthy young child may heal completely in four weeks while the same fracture in a 65 year old smoker may not heal completely for several years.",
"   </p>",
"   <p>",
"    The initial inflammatory phase is dominated by vascular events. Following a fracture, a hematoma forms which provides the building blocks for healing. Subsequently, reabsorption occurs of the 1 to 2 mm of bone at the fracture edges that have lost their blood supply. It is this bone reabsorption that makes fracture lines become radiographically distinct 5 to 10 days after injury. Next, multipotent cells are transformed into osteoprogenitor cells, which begin to form new bone.",
"   </p>",
"   <p>",
"    In the reparative phase, new blood vessels develop from outside the bone that supplies nutrients to the cartilage, which begins to form across the fracture site. Nearly complete immobilization is desirable during both the inflammatory phase and the early reparative phase to allow for the growth of these new vessels. However, once neovascularization is complete, progressive loading and motion of the fracture site are desirable to augment callus formation.",
"   </p>",
"   <p>",
"    Callus typically forms as a collar of new, endochondral bone around the fractured area. This callus is initially highly cartilaginous, but hardens as mineralization and endochondral calcification occur during the remodeling phase. Late in the reparative phase, clinical union of the fracture occurs. Clinical union occurs when the fractured bone does not shift on clinical examination, the fracture site is nontender, and the patient can use the injured limb without significant pain. Because the initial callus is cartilaginous, clinical union may occur before evidence of radiographic union is appreciable on x-rays. Clinical union classically marks the end of the reparative phase of fracture healing.",
"   </p>",
"   <p>",
"    In the remodeling phase, the endochondral callus becomes completely ossified and the bone undergoes structural remodeling. The process of remodeling occurs quickly in young children, who remodel their entire skeleton every year. By late childhood, the rate of skeletal remodeling is approximately 10 percent per year and continues near this level throughout life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43941/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to patient age, other factors affecting the rate of bone remodeling include thyroid and growth hormone levels, calcitonin, glucocorticoids, and nutritional status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43941/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Common conditions that impair fracture healing include diabetes mellitus, arteriovascular disease, anemia, hypothyroidism, malnutrition (eg, vitamin C or D deficiencies, inadequate protein intake), excessive chronic alcohol use, and tobacco use. Specific medications may also impair fracture healing, including nonsteroidal antiinflammatory drugs, glucocorticoids, and certain antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17593?source=see_link\">",
"     \"Bone disease with hyperthyroidism and thyroid hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/26/11687?source=see_link\">",
"     \"Bone disease in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link&amp;anchor=H23#H23\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Possible effect on fracture healing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FRACTURE DESCRIPTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential first step of fracture treatment is to precisely identify the type of fracture present. At a minimum, a fracture should be identified using the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Name of the injured bone",
"     </li>",
"     <li>",
"      Location of the injury (eg, dorsal or volar; metaphysis, diaphysis, or epiphysis)",
"     </li>",
"     <li>",
"      Orientation of the fracture (eg, transverse, oblique, spiral)",
"     </li>",
"     <li>",
"      Condition of the overlying tissues (eg, open or closed fracture).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other important descriptors include fracture angulation, comminution, and displacement. Each aspect of fracture description is discussed below and diagrams depicting common fracture types are provided (",
"    <a class=\"graphic graphic_figure graphicRef56313 \" href=\"mobipreview.htm?16/19/16697\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69080 \" href=\"mobipreview.htm?39/31/40441\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fractures are described based upon the radiographs obtained. A table describing the most common x-ray views according to injury location is provided (",
"    <a class=\"graphic graphic_table graphicRef66310 \" href=\"mobipreview.htm?40/10/41131\">",
"     table 1",
"    </a>",
"    ). See the topic reviews dealing with specific fractures for additional information about the radiographs needed for these injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Location: bone and aspect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper fracture description begins with precise identification of the injured bone. Lay terminology such as \"finger\" or \"wrist\" should be avoided; precise anatomic terms, such as \"proximal phalanx\" or \"scaphoid\" should be used.",
"   </p>",
"   <p>",
"    Once the fractured bone is identified, the aspect of the injury is described using precise anatomic terms (",
"    <a class=\"graphic graphic_figure graphicRef53947 \" href=\"mobipreview.htm?7/61/8147\">",
"     figure 3",
"    </a>",
"    ). \"Medial\" and \"lateral\" are such common and precise descriptors. With hand and forearm fractures, the descriptors \"radial\" and \"ulnar\" are used instead of medial and lateral, and \"dorsal\" and \"palmar\" are used instead of anterior and posterior.",
"   </p>",
"   <p>",
"    Long bone fractures should be described using the involved regions of the bone: metaphysis, diaphysis, or epiphysis (",
"    <a class=\"graphic graphic_figure graphicRef56313 \" href=\"mobipreview.htm?16/19/16697\">",
"     figure 1",
"    </a>",
"    ). Diaphyseal fractures are further characterized as involving the proximal, middle, or distal third of the bone, or the junction between two of these regions.",
"   </p>",
"   <p>",
"    Fractures that extend into a joint space are referred to as \"intra-articular.\" Intraarticular fractures are generally more serious injuries and commonly require surgery since optimal healing requires precise anatomic reduction. Intraarticular fractures are characterized by the percentage of the joint space they disrupt. As an example, a fracture of the distal interphalangeal joint where one third of the affected bone is displaced is described as involving 30 percent of the joint space.",
"   </p>",
"   <p>",
"    Some fractures are associated with unique names that are more easily identifiable and descriptive than the traditional anatomic approach. For instance, a \"supracondylar fracture\" is more recognizable, descriptive, and concise than a \"fracture of the distal humerus at the metaphyseal-diaphyseal junction.\" A table listing several of these common fractures is provided (",
"    <a class=\"graphic graphic_table graphicRef50166 \" href=\"mobipreview.htm?9/10/9388\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The Salter-Harris classification scheme is used to describe fractures involving the growth plate (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"     figure 4",
"    </a>",
"    ). The risk of complications involving the growth plate increases in parallel with the Salter-Harris type (ie, type I fractures are at low risk and type V are at greatest). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=see_link\">",
"     \"General principles of fracture management: Fracture patterns and description in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Orientation: Transverse, oblique, and spiral",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fracture line may have one of three possible orientations: transverse, oblique, or spiral (",
"    <a class=\"graphic graphic_figure graphicRef69080 \" href=\"mobipreview.htm?39/31/40441\">",
"     figure 2",
"    </a>",
"    ). Transverse fracture lines travel perpendicular to the long axis of the bone. Typically caused by a direct force causing the bone to bend, fractures with a transverse orientation are the most common fracture type.",
"   </p>",
"   <p>",
"    Oblique and spiral fractures run diagonally down the long axis of a bone. Oblique fracture lines are typically shorter than those of spiral fractures, and result from twisting or rotary forces. Long oblique fractures may easily be mistaken for spiral fractures. In a true spiral fracture, a severe rotary force causes the bone to splinter, disrupting the bone in a characteristic pattern that involves a fracture line that travels in two different oblique directions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69325 \" href=\"mobipreview.htm?32/6/32879\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59161 \" href=\"mobipreview.htm?20/34/21026\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Displacement and angulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fracture is either angulated or displaced if it results in the loss of normal anatomic alignment. Angulated or displaced fractures commonly result in more severe soft tissue injuries than nondisplaced fractures. By convention, any fracture malalignment is described by referring to movement of the distal fragment relative to the proximal bone.",
"   </p>",
"   <p>",
"    Displacement describes movement when two ends of a fracture move away from each other in an anterior-posterior plane or a medial-lateral plane. It can be quantified by the percentage of bone that is malaligned. For instance, a femur fracture where only 25 percent of the fracture surfaces remain in contact might be described as \"75 percent medially displaced.\" Displacement can also be quantified in millimeters of displacement. Special cases of displacement occur when fracture ends are crushed together (\"impacted\") or pulled apart (\"distracted\").",
"   </p>",
"   <p>",
"    Angulation refers to motion relative to the long axis of the bone. When describing angulation, both the direction and the degree (ie, angle formed by the major bone fragments) of malformation are important. The direction of angulation is best communicated by identifying the orientation of the fracture apex. In other words, the fracture fragments will form a V shape, and the apex is the point of the V. The direction of the apex is used to describe the fracture. The amount of angulation is typically reported in degrees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fractures with multiple parts",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Comminution versus segmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures that create more than two fracture fragments from the same bone are called comminuted (",
"    <a class=\"graphic graphic_figure graphicRef53947 \" href=\"mobipreview.htm?7/61/8147\">",
"     figure 3",
"    </a>",
"    ). Recognizing comminution has important implications since many comminuted fractures require surgical treatment. The degree of comminution is directly proportional to the force of injury; comminuted fractures are associated with more severe soft tissue injuries.",
"   </p>",
"   <p>",
"    Segmental fractures occur when two fracture lines divide the bone into three or more large pieces. Segmental fractures are associated with poorer outcomes, the need for surgical fixation, and significant accompanying soft tissue injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Compression and impaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression and impaction describe fractures when bones or fragments are driven into one another. Compression fractures occur in vertebral bodies and lead to a collapse of the endplates. Impacted fractures occur when forces exerted down the length of a long bone drive one fracture fragment into the other, \"telescoping\" them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Open versus closed fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open fractures are those in contact with the outside environment (ie, open to air), and represent orthopedic emergencies requiring immediate irrigation and debridement in the operating room and treatment with intravenous antibiotics. This decreases the risk of osteomyelitis and other infectious complications. In addition to infection, open fractures are associated with higher rates of compartment syndrome, neurovascular injury, and other soft tissue injuries compared with closed fractures.",
"   </p>",
"   <p>",
"    Sometimes open fractures are obvious, as the bone can be seen protruding through the skin. More often, skin covers the involved bone, leaving a small skin laceration or puncture wound as the only sign. A careful examination of the wound is necessary.",
"   </p>",
"   <p>",
"    Of note, hand surgeons generally do not consider minor fractures of the distal phalanx with small adjacent lacerations or nailbed injuries to be open fractures requiring emergent treatment, even though they may technically meet the definition of an open fracture.",
"   </p>",
"   <p>",
"    The severity of open fractures may be classified using the following system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43941/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 &ndash; Puncture wound (&le;1 cm) with minimal contamination and minimal muscle injury.",
"     </li>",
"     <li>",
"      Type 2 &ndash; Laceration (&gt;1 cm) with moderate soft tissue damage.",
"     </li>",
"     <li>",
"      Type 3 &ndash; Extensive soft tissue damage with severe crush injury of muscle and massive contamination, including comminuted bone fragments (type 3A), periosteal stripping (type 3B), or arterial injury requiring repair (type 3C).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PRECISE \"RADIOGRAPHIC\" DESCRIPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using the framework presented above, the clinician can convey a complete verbal snapshot of a fracture using few words. For providers with less experience managing orthopedic injuries, a simple Fracture Description Tool can be helpful to practice describing fractures or to make sure terminology is accurate before calling a consultant (",
"    <a class=\"graphic graphic_figure graphicRef65549 \" href=\"mobipreview.htm?31/39/32382\">",
"     figure 5",
"    </a>",
"    ). To use the tool, choose a word provided for each italicized category. The sentences produced should completely and precisely describe the fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3492062\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone is a composite structure with mineral and organic components. The mineral skeleton provides strength, stiffness, and rigidity. The organic or protein component consists primarily of type I collagen, which lends tensile strength and resiliency. The outer covering of bone, the periosteum, provides the vascular supply that plays an essential role in fracture healing. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Biology of bone healing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following fracture, bone healing occurs in three slightly overlapping stages: inflammatory, reparative, and remodeling. Each phase is described in the text.",
"     </li>",
"     <li>",
"      Healing rates vary widely according to patient age, comorbidities, and other factors such as thyroid and growth hormone levels, calcitonin levels, and nutritional status. Common conditions that impair fracture healing include diabetes mellitus, arteriovascular disease, anemia, hypothyroidism, malnutrition (eg, vitamin C or D deficiencies, inadequate protein intake), excessive chronic alcohol use, and tobacco use. Specific medications may also impair fracture healing, including nonsteroidal antiinflammatory drugs, glucocorticoids, and certain antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The essential first step of fracture treatment is to identify precisely the type of fracture present. At a minimum, a fracture should be identified using the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Name of the injured bone",
"     </li>",
"     <li>",
"      Location of the injury (eg, dorsal or volar; metaphysis, diaphysis, or epiphysis)",
"     </li>",
"     <li>",
"      Orientation of the fracture (eg, transverse, oblique, spiral)",
"     </li>",
"     <li>",
"      Condition of the overlying tissues (eg, open or closed fracture)",
"      <br/>",
"      <br/>",
"      Other important descriptors include fracture angulation, comminution, and displacement. Each aspect of fracture description is discussed in the text; diagrams depicting common fracture types are provided (",
"      <a class=\"graphic graphic_figure graphicRef56313 \" href=\"mobipreview.htm?16/19/16697\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef69080 \" href=\"mobipreview.htm?39/31/40441\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fracture description'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open fractures are those in contact with the outside environment (ie, open to air), and represent orthopedic emergencies requiring, in the large majority of cases, immediate irrigation and debridement in the operating room and treatment with intravenous antibiotics. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Open versus closed fractures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Eiff MP, Hatch RL. Fracutre Management for Primary Care, 3rd, Elsevier Saunders, Philadelphia 2012. p.26.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43941/abstract/2\">",
"      Wilkins KE. Principles of fracture remodeling in children. Injury 2005; 36 Suppl 1:A3.",
"     </a>",
"    </li>",
"    <li>",
"     Jones ET. Skeletal growth and development as related to trauma. In: Skeletal Trauma in Children, 3rd, Green NE, Swiontkowski MF.  (Eds), Saunders, Philadelphia 2003. p.6.",
"    </li>",
"    <li>",
"     McGowan HJ. Sports Medicine Reource Manual, 1st, Seidenberg P, Beutler AL.  (Eds), Saunders, Philadelphia 2007. p.147.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43941/abstract/5\">",
"      Macmahon P, Eustace SJ. General principles. Semin Musculoskelet Radiol 2006; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43941/abstract/6\">",
"      Tsiridis E, Upadhyay N, Giannoudis P. Molecular aspects of fracture healing: which are the important molecules? Injury 2007; 38 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43941/abstract/7\">",
"      Dimitriou R, Tsiridis E, Giannoudis PV. Current concepts of molecular aspects of bone healing. Injury 2005; 36:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43941/abstract/8\">",
"      Buckwalter JA, Glimcher MJ, Cooper RR, Recker R. Bone biology. I: Structure, blood supply, cells, matrix, and mineralization. Instr Course Lect 1996; 45:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43941/abstract/9\">",
"      Gaston MS, Simpson AH. Inhibition of fracture healing. J Bone Joint Surg Br 2007; 89:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43941/abstract/10\">",
"      Gustilo RB, Mendoza RM, Williams DN. Problems in the management of type III (severe) open fractures: a new classification of type III open fractures. J Trauma 1984; 24:742.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 220 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43941=[""].join("\n");
var outline_f42_58_43941=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3492062\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOLOGY OF BONE HEALING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FRACTURE DESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Location: bone and aspect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Orientation: Transverse, oblique, and spiral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Displacement and angulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fractures with multiple parts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Comminution versus segmentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Compression and impaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Open versus closed fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PRECISE \"RADIOGRAPHIC\" DESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3492062\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/220\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/220|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/6/32879\" title=\"diagnostic image 1\">",
"      Spiral frac tibial shaft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/34/21026\" title=\"diagnostic image 2\">",
"      Oblique fracture of the fifth metatarsal shaft",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/220|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/19/16697\" title=\"figure 1\">",
"      Fracture classification one",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/31/40441\" title=\"figure 2\">",
"      Fracture classification two",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/61/8147\" title=\"figure 3\">",
"      Anatomic position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/55/21361\" title=\"figure 4\">",
"      Salter-Harris classification system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/39/32382\" title=\"figure 5\">",
"      Fracture identification practice tool",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/220|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/10/41131\" title=\"table 1\">",
"      Common x-ray views by fracture location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/10/9388\" title=\"table 2\">",
"      Unique fracture terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/26/11687?source=related_link\">",
"      Bone disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17593?source=related_link\">",
"      Bone disease with hyperthyroidism and thyroid hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=related_link\">",
"      General principles of fracture management: Fracture patterns and description in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_58_43942="Hemicrania continua";
var content_f42_58_43942=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hemicrania continua",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/58/43942/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/58/43942/contributors\">",
"     Ivan Garza, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/58/43942/contributors\">",
"     Todd J Schwedt, MD, MSCI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/58/43942/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/58/43942/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/58/43942/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/58/43942/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/58/43942/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic daily headache is a descriptive term that encompasses several different specific headache diagnoses characterized by frequent headaches. Chronic daily headache types with individual headaches of long duration (ie, four hours or more) include chronic migraine (",
"    <a class=\"graphic graphic_table graphicRef56064 \" href=\"mobipreview.htm?33/14/34027\">",
"     table 1",
"    </a>",
"    ), chronic tension-type headache (",
"    <a class=\"graphic graphic_table graphicRef68892 \" href=\"mobipreview.htm?38/22/39275\">",
"     table 2",
"    </a>",
"    ), medication overuse headache (",
"    <a class=\"graphic graphic_table graphicRef71798 \" href=\"mobipreview.htm?8/35/8763\">",
"     table 3",
"    </a>",
"    ), hemicrania continua (",
"    <a class=\"graphic graphic_table graphicRef62652 \" href=\"mobipreview.htm?29/56/30603\">",
"     table 4",
"    </a>",
"    ), and new daily persistent headache (",
"    <a class=\"graphic graphic_table graphicRef76010 \" href=\"mobipreview.htm?34/48/35595\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will discuss hemicrania continua, a unilateral headache that is continuous in nature. Other types of chronic daily headache are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37830?source=see_link\">",
"     \"Overview of chronic daily headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"hemicrania continua\" was coined in 1984 when the first cases were described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/1\">",
"     1",
"    </a>",
"    ]. The true frequency of hemicrania continua (HC) in the general population is unknown, and only a few hundred cases have been published in the literature. However, one headache center identified 34 new cases of HC in three years, suggesting the disorder is more common than previously considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HC tends to have onset in the third decade of life, but with a range from the first to seventh decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/2\">",
"     2",
"    </a>",
"    ]. It is more common in women than men, with an estimated female to male ratio of 2:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the name implies, HC is a unilateral headache that is continuous in nature. Pain is most commonly located anteriorly in the orbit, frontal regions, and temporal regions, but pain in the occiput is not rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/4\">",
"     4",
"    </a>",
"    ]. Involvement of other regions of the head and neck has also been described.",
"   </p>",
"   <p>",
"    Although pain is continuous, it fluctuates in severity with superimposed attacks of more severe pain. Pain exacerbations last from minutes to several days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/5\">",
"     5",
"    </a>",
"    ]. Pain intensity ranges from mild to severe, but the pain of HC is not as excruciatingly severe as the pain of cluster headache.",
"   </p>",
"   <p>",
"    During episodes of superimposed severe pain, there is usually evidence of cranial autonomic activation. The most common cranial autonomic feature is lacrimation, followed by nasal congestion, conjunctival injection, ptosis, and facial flushing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/6\">",
"     6",
"    </a>",
"    ]. Less common autonomic features include rhinorrhea, sweating, eyelid edema, miosis, mydriasis, and facial edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/6\">",
"     6",
"    </a>",
"    ]. The autonomic features are generally less prominent than those seen with the trigeminal autonomic cephalalgias (eg, cluster headache and paroxysmal hemicrania). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25545?source=see_link\">",
"     \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a sense of ocular discomfort, as if there is something in the eye (termed the false foreign body sensation), is often reported by patients with HC.",
"   </p>",
"   <p>",
"    Although mild migrainous features are occasionally present with HC, they are most often absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/7\">",
"     7",
"    </a>",
"    ]. Less common clinical features that have been attributed to HC include a preceding aura, transition from episodic headaches (hemicrania episodica) to HC, side-alternating attacks, bilateral pain, and evolution from cluster headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/3,8,9\">",
"     3,8,9",
"    </a>",
"    ]. Whether these are truly features of HC as opposed to similar headache disorders remains to be seen.",
"   </p>",
"   <p>",
"    Superimposed jabs and jolts (stabbing headache) occur frequently in patients with HC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, some patients with HC also have primary stabbing headache and would be diagnosed with both headache types.",
"   </p>",
"   <p>",
"    Primary stabbing headache refers to brief, sharp, or jabbing pain in the head that occurs either as a single episode or in brief repeated volleys. The pain is usually over the ophthalmic trigeminal distribution while the face is generally spared. The pain usually lasts a fraction of a second, but can persist for up to one minute and recurs at irregular intervals (hours to days). The attacks commonly subside with the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13714?source=see_link\">",
"     \"Primary stabbing headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Absolute response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    therapy is required for the diagnosis of HC. This is discussed in greater detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The posterior hypothalamus and dorsal rostral pons play a role in the physiology of HC. A controlled positron emission tomography (PET) study of seven patients with HC showed significant activation of the contralateral posterior hypothalamus and ipsilateral rostral pons during baseline pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/10\">",
"     10",
"    </a>",
"    ]. This activation was blocked by administration of intramuscular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    It is hypothesized that the presence of autonomic nervous system symptoms in HC is due, at least in part, to hypothalamic activation with secondary disinhibition of the trigeminal-autonomic reflex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/11\">",
"     11",
"    </a>",
"    ]. A similar mechanism may be implicated in cluster headache and the SUNCT and SUNA headache syndromes. The exact role of the dorsal rostral pons in HC is unclear, but this region is also activated in migraine, and may play a role in the inhibition of nociceptive traffic along the trigeminovascular system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HC is dependent upon the clinical features of the headache and the response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    . Diagnostic criteria, as published in the International Classification of Headache Disorders 2nd edition, are as follows (",
"    <a class=\"graphic graphic_table graphicRef62652 \" href=\"mobipreview.htm?29/56/30603\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A. Headache for more than three months fulfilling criteria B through D",
"     </li>",
"     <li>",
"      B. All of the following characteristics:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Unilateral pain without side-shift",
"     </li>",
"     <li>",
"      Daily and continuous, without pain-free periods",
"     </li>",
"     <li>",
"      Moderate intensity, but with exacerbations of severe pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C. At least one of the following autonomic features occurs during exacerbations and ipsilateral to the side of pain:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Conjunctival injection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lacrimation",
"     </li>",
"     <li>",
"      Nasal congestion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rhinorrhea",
"     </li>",
"     <li>",
"      Ptosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      miosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      D. Complete response to therapeutic doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"     </li>",
"     <li>",
"      E. Not attributed to another disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the definition of HC, some patients with the clinical phenotype of HC do not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , and some do not report cranial autonomic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A retrospective report from a tertiary headache center identified 165 patients seen from 1998 to 2007 with a putative diagnosis of HC who then had an adequate trial of indomethacin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/13\">",
"     13",
"    </a>",
"    ]. An absolute response to indomethacin was observed in only 43 patients (26 percent). Furthermore, no predictors for indomethacin response were identified. This included the presence of autonomic symptoms, which were present in 57 percent of indomethacin responsive and 61 percent of indomethacin nonresponsive patients.",
"   </p>",
"   <p>",
"    The lack of predictors for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    response led the investigators to suggest that all patients with continuous side-locked primary headaches receive an indomethacin trial (in the absence of contraindications to indomethacin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the strength of this finding and recommendation is limited by the retrospective study design and sample size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnostic indomethacin trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;As currently defined, the diagnosis of HC requires complete responsiveness to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    . Either oral or parenteral indomethacin (where available) can be used to confirm the diagnosis of HC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      test can be used for the diagnosis of HC. Indomethacin doses ranging from 25 mg to 300 mg a day have been reported effective. Although there are variations in recommended titration schedules and dosages, we suggest a nine day trial of oral indomethacin. During the nine day trial, patients increase the indomethacin dose every three days (up to a maximum total daily dose of 200 mg) unless they have resolution of headache, in which case they continue at the effective dose. The starting dose is indomethacin 50 mg twice daily for three days; the dose can then be increased if necessary to 50 mg three times daily for three days, followed by 50 mg four times daily for three days. Completion of the test without headache resolution is considered a failed trial.",
"     </li>",
"     <li>",
"      Parenteral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      given intramuscularly (the \"indotest\") has been used in clinical research as a standardized diagnostic test of HC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/15\">",
"       15",
"      </a>",
"      ]. The indotest can also be applied in clinical practice for patient diagnosis. However, parenteral indomethacin for this purpose is NOT available in the United States. The test involves administration of intramuscular (IM) indomethacin 50 mg to a patient who otherwise meets the clinical criteria for HC. In an open-label study of the indotest that included 12 patients with HC, administration of indomethacin 50 mg IM resulted in pain resolution after a mean interval from injection of 73 minutes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/15\">",
"       15",
"      </a>",
"      ]. This beneficial effect endured for a mean of 13 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/15\">",
"       15",
"      </a>",
"      ]. In four patients treated with indomethacin 100 mg IM, resolution of pain was noted after a mean of 61 minutes and the benefit endured for a mean of 13 hours. The indotest is also used for the diagnosis of paroxysmal hemicrania, another indomethacin-responsive primary headache disorder. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25545?source=see_link\">",
"       \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest performing a brain MRI scan for all patients with suspected HC to exclude a structural brain lesion, particularly one involving the pituitary fossa. Even cases fitting all criteria for HC, including a complete response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , can have a secondary etiology. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of primary HC - a strictly unilateral, continuous headache with superimposed exacerbations accompanied by autonomic features and migrainous symptoms - includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary hemicrania continua",
"     </li>",
"     <li>",
"      Chronic migraine",
"     </li>",
"     <li>",
"      Trigeminal autonomic cephalalgias:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cluster headache",
"     </li>",
"     <li>",
"      The syndromes of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)",
"     </li>",
"     <li>",
"      Paroxysmal hemicrania",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Secondary hemicrania continua",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are case reports of headaches mimicking primary HC (including response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    ) that are found to be secondary in nature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. Underlying etiologies have included internal carotid artery dissection, unruptured cerebral aneurysm, pineal cyst, pituitary tumor, ipsilateral mesenchymal tumor of the sphenoidal bone involving the clinoid process at the base of the skull, lung adenocarcinoma, and pontine stroke.",
"   </p>",
"   <p>",
"    Secondary HC should be considered when any of the following conditions are present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The clinical picture is atypical",
"     </li>",
"     <li>",
"      There are associated neurologic signs",
"     </li>",
"     <li>",
"      The treatment response is poor",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;While migrainous features are occasionally present with HC, they are most often absent. Nevertheless, chronic migraine, when strictly unilateral and side-locked, can be confused with hemicrania continua. Autonomic features (eg, nasal congestion, rhinorrhea, lacrimation) can be associated with migraine headache, although they are typically less prominent than those seen with HC or the trigeminal autonomic cephalalgias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7128?source=see_link\">",
"     \"Chronic migraine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Trigeminal autonomic cephalalgias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trigeminal autonomic cephalalgias are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features (eg, ptosis, miosis, lacrimation, conjunctival injection, rhinorrhea, and nasal congestion). Cluster headache, SUNCT and SUNA headache syndromes, and paroxysmal hemicrania are types of trigeminal autonomic cephalalgias that may occasionally be confused with HC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cluster headache is characterized by attacks of severe unilateral orbital, supraorbital, or temporal pain, accompanied by ipsilateral autonomic phenomena. Attacks usually last 15 to 180 minutes. In the episodic form, attacks occur daily, usually for weeks, followed by a period of remission. The chronic form of cluster headache lacks sustained remissions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=see_link\">",
"       \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The syndromes of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) are characterized by sudden brief attacks of severe unilateral head pain in orbital, periorbital, or temporal regions, accompanied by ipsilateral cranial autonomic symptoms. The attack duration with SUNCT is 5 to 240 seconds, with 3 to 200 attacks per day. For SUNA, the attack duration ranges from two seconds to 10 minutes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28648?source=see_link\">",
"       \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paroxysmal hemicrania is characterized by unilateral, brief, severe attacks of pain associated with ipsilateral cranial autonomic features that recur several times per day. The headache is most often in the ophthalmic trigeminal distribution and lasts 2 to 30 minutes. The mean attack frequency is 11 to 14 daily. The syndrome is exquisitely responsive to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25545?source=see_link\">",
"       \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Features that help to distinguish HC and the trigeminal autonomic cephalalgias include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By definition, headache attacks are short-lasting with SUNCT and SUNA (&le;10 minutes) and paroxysmal hemicrania (&le;30 minutes), and even cluster attacks are usually relatively short-lived (&le;180 minutes). In contrast, the pain in HC is continuous.",
"     </li>",
"     <li>",
"      In general, the pain of HC is not as excruciatingly severe as the pain of the trigeminal autonomic cephalalgias",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     Indomethacin",
"    </a>",
"    is the treatment of choice for HC. As currently defined, the diagnosis of HC requires complete responsiveness to indomethacin. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Contraindications to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    discontinuation due to intolerance have led to the search for alternative therapies. There are case reports of improvement with cyclooxygenase-2 inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , melatonin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , and occipital nerve stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/3,22-26\">",
"     3,22-26",
"    </a>",
"    ]. However, the actual benefit of each of these treatments should be considered unknown until larger studies are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Indomethacin dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with HC, the response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    is generally quite fast, although the appropriate dose varies. The initial dose is that which results in resolution of headache, and is determined during the diagnostic indomethacin trial. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Diagnostic indomethacin trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, it is desirable to find the lowest effective",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    dose, given its potential adverse effects.",
"   </p>",
"   <p>",
"    These points are illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study, 12 patients with HC discontinued",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      until headache recurred [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/27\">",
"       27",
"      </a>",
"      ]. Oral indomethacin was then restarted, based upon prior dosage, at either 25 or 50 mg every eight hours until complete resolution of pain. The cumulative amount of indomethacin necessary to abort pain ranged from 25 mg to 150 mg. Complete pain relief was obtained within 8, 24, and 48 hours in 9, 10, and 12 patients, respectively.",
"     </li>",
"     <li>",
"      In a retrospective study, 16 adults with HC were started on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (25 mg every eight hours), and the dose was adjusted up or down as needed after two weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/58/43942/abstract/28\">",
"       28",
"      </a>",
"      ]. Complete and sustained symptomatic relief was achieved with a mean daily indomethacin dose of 78 mg (&plusmn; 22 mg). After six months of treatment, patients were given the option of decreasing the daily indomethacin dose by 25 mg every week until they were either off the medication or until the pain returned. With this strategy, the mean daily dose at last follow-up (approximately three to four years) was 61 mg (&plusmn; 37 mg). Seven patients were able to reduce the dose by a significant 56 percent, eight did not have any significant dosage change, and one required a dose increase from 75 mg to 100 mg daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Indomethacin side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential side effects from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    include gastrointestinal injury, bleeding from platelet inhibition, exacerbation of anemia, hepatic dysfunction, renal dysfunction, exacerbation of hypertension, exacerbation of congestive heart failure, dizziness, and others. Many of these side effects are dose-related. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common serious side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    is the development of peptic ulcers. Measures to prevent gastrointestinal side effects include testing and treating for Helicobacter pylori, and the use of gastroprotection with proton pump inhibitors or, less often,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    . These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link&amp;anchor=H10#H10\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Prevention strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     Indomethacin",
"    </a>",
"    suppositories are occasionally helpful if gastric intolerance is a major problem, or when high doses, such as 300 mg daily, are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemicrania continua (HC) is a strictly unilateral, continuous headache with superimposed exacerbations of moderate to severe intensity accompanied by autonomic features and sometimes by migrainous symptoms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The true frequency of HC in the general population is unknown. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The posterior hypothalamus and dorsal rostral pons play a role in the physiology of HC. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HC is dependent upon the clinical features of the headache and the response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef62652 \" href=\"mobipreview.htm?29/56/30603\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Either oral or parenteral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (where available) can be used to confirm the diagnosis of HC. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnostic indomethacin trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with suspected HC, we suggest performing a brain MRI scan to exclude a structural brain lesion. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of primary HC includes secondary HC, chronic migraine, cluster headache, SUNCT and SUNA headache syndromes, and paroxysmal hemicrania. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       Indomethacin",
"      </a>",
"      is the treatment of choice for HC. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/1\">",
"      Sjaastad O, Spierings EL. \"Hemicrania continua\": another headache absolutely responsive to indomethacin. Cephalalgia 1984; 4:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/2\">",
"      Peres MF, Silberstein SD, Nahmias S, et al. Hemicrania continua is not that rare. Neurology 2001; 57:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/3\">",
"      Dodick D. Hemicrania continua: diagnostic criteria and nosologic status. Cephalalgia 2001; 21:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/4\">",
"      Bordini C, Antonaci F, Stovner LJ, et al. \"Hemicrania continua\": a clinical review. Headache 1991; 31:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/5\">",
"      Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalgias and hemicrania continua. Drugs 2003; 63:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/6\">",
"      Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain 2010; 133:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/7\">",
"      Bigal ME, Tepper SJ, Rapoport AM, Sheftell FD. Hemicrania continua: comparison between two different classification systems. Cephalalgia 2002; 22:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/8\">",
"      Peres MF, Siow HC, Rozen TD. Hemicrania continua with aura. Cephalalgia 2002; 22:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/9\">",
"      Matharu MS, Bradbury P, Swash M. Hemicrania continua: side alternation and response to topiramate. Cephalalgia 2006; 26:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/10\">",
"      Matharu MS, Cohen AS, McGonigle DJ, et al. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache 2004; 44:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/11\">",
"      Goadsby PJ, Matharu MS, Boes CJ. SUNCT syndrome or trigeminal neuralgia with lacrimation. Cephalalgia 2001; 21:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/12\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/13\">",
"      Marmura MJ, Silberstein SD, Gupta M. Hemicrania continua: who responds to indomethacin? Cephalalgia 2009; 29:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/14\">",
"      Prakash S, Golwala P. A proposal for revision of hemicrania continua diagnostic criteria based on critical analysis of 62 patients. Cephalalgia 2012; 32:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/15\">",
"      Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the 'indotest'. Headache 1998; 38:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/16\">",
"      Eross EJ, Swanson JW, Dodick DW. Hemicrania continua: an indomethacin-responsive case with an underlying malignant etiology. Headache 2002; 42:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/17\">",
"      Antonaci F, Sjaastad O. Hemicrania continua: a possible symptomatic case, due to mesenchymal tumor. Funct Neurol 1992; 7:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/18\">",
"      Valen&ccedil;a MM, Andrade-Valen&ccedil;a LP, da Silva WF, Dodick DW. Hemicrania continua secondary to an ipsilateral brainstem lesion. Headache 2007; 47:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/19\">",
"      Rogalewski A, Evers S. Symptomatic hemicrania continua after internal carotid artery dissection. Headache 2005; 45:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/20\">",
"      Peres MF, Zukerman E, Porto PP, Brandt RA. Headaches and pineal cyst: a (more than) coincidental relationship? Headache 2004; 44:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/21\">",
"      Levy MJ, Matharu MS, Meeran K, et al. The clinical characteristics of headache in patients with pituitary tumours. Brain 2005; 128:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/22\">",
"      Peres MF, Silberstein SD. Hemicrania continua responds to cyclooxygenase-2 inhibitors. Headache 2002; 42:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/23\">",
"      Rozen TD. Verapamil-responsive hemicrania continua in a patient with episodic cluster headache. Cephalalgia 2006; 26:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/24\">",
"      Spears RC. Hemicrania continua: a case in which a patient experienced complete relief on melatonin. Headache 2006; 46:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/25\">",
"      Rozen TD. Melatonin responsive hemicrania continua. Headache 2006; 46:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/26\">",
"      Schwedt TJ, Dodick DW, Hentz J, et al. Occipital nerve stimulation for chronic headache--long-term safety and efficacy. Cephalalgia 2007; 27:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/27\">",
"      Pareja J, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Interval between indomethacin administration and response. Headache 1996; 36:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43942/abstract/28\">",
"      Pareja JA, Caminero AB, Franco E, et al. Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua. Cephalalgia 2001; 21:906.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3342 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-9B44C2D3FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43942=[""].join("\n");
var outline_f42_58_43942=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnostic indomethacin trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Secondary hemicrania continua",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Trigeminal autonomic cephalalgias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Indomethacin dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Indomethacin side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3342\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3342|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/14/34027\" title=\"table 1\">",
"      Chronic migraine diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/22/39275\" title=\"table 2\">",
"      Chronic tension-type headache criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/35/8763\" title=\"table 3\">",
"      Medication overuse headache criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/56/30603\" title=\"table 4\">",
"      Hemicrania continua diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/48/35595\" title=\"table 5\">",
"      New daily persistent headache criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7128?source=related_link\">",
"      Chronic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37830?source=related_link\">",
"      Overview of chronic daily headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25545?source=related_link\">",
"      Paroxysmal hemicrania: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13714?source=related_link\">",
"      Primary stabbing headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28648?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_58_43943="Cimetidine: Pediatric drug information";
var content_f42_58_43943=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cimetidine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"    see \"Cimetidine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/30/27109?source=see_link\">",
"    see \"Cimetidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tagamet HB 200&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F151516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cimetidine&reg;;",
"     </li>",
"     <li>",
"      Dom-Cimetidine;",
"     </li>",
"     <li>",
"      Mylan-Cimetidine;",
"     </li>",
"     <li>",
"      Novo-Cimetidine;",
"     </li>",
"     <li>",
"      Nu-Cimet;",
"     </li>",
"     <li>",
"      PMS-Cimetidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Histamine H",
"       <sub>",
"        2",
"       </sub>",
"       Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: 5-10 mg/kg/day in divided doses every 8-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"      see \"Cimetidine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants: 10-20 mg/kg/day divided every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 20-40 mg/kg/day in divided doses every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Short-term treatment of active ulcers: 300 mg 4 times/day or 800 mg at bedtime or 400 mg twice daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duodenal ulcer prophylaxis: 400-800 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastric hypersecretory conditions: 300-600 mg every 6 hours; dosage not to exceed 2.4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GERD: 800 mg twice daily or 400 mg 4 times/day for 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acid indigestion, heartburn, sour stomach relief (OTC use): 100 mg right before or up to 30 minutes before a meal; no more than 2 tablets per day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment using 5-10 mg/kg/dose in children or 300 mg in adults",
"     </b>",
"     (titrate dose to gastric pH and Cl",
"     <sub>",
"      cr",
"     </sub>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;40 mL/minute: Administer every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-40 mL/minute: Administer every 8 hours or reduce dose by 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer every 12 hours or reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Administer after dialysis and every 12 hours during the interdialysis period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Reduce dosage in severe liver disease",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F151488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride [strength expressed as base]: 300 mg/5 mL (237 mL, 473 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg, 300 mg, 400 mg, 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tagamet HB 200&reg;: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F151472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Administer with food; do not administer with antacids",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light; store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of active duodenal ulcers and benign gastric ulcers; long-term prophylaxis of duodenal ulcer; gastric hypersecretory states; gastroesophageal reflux (GERD); over-the-counter (OTC) formulation for relief of acid indigestion, heartburn, or sour stomach",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F151577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cimetidine may be confused with simethicone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F151574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: AV block, bradycardia, hypotension, tachycardia, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Agitation, confusion, dizziness, fever, headache, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Alopecia, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Edema of the breasts, gynecomastia, sexual ability decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, nausea, pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, hemolytic anemia (immune-based), neutropenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: ALT increased, AST increased, hepatic fibrosis (case report)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, polymyositis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Creatinine increased, interstitial nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylaxis, pneumonia (causal relationship not established)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cimetidine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Modify dosage in patients with renal and/or hepatic impairment; multiple drug interactions exist requiring dose modifications of other medications or cimetidine.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of gastric acid inhibitors including proton pump inhibitors and H",
"     <sub>",
"      2",
"     </sub>",
"     blockers has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia (Canani, 2006). A large epidemiological study has suggested an increased risk for developing pneumonia in patients receiving H",
"     <sub>",
"      2",
"     </sub>",
"     receptor antagonists; however, a causal relationship with cimetidine has not been demonstrated. A cohort analysis including over 11,000 neonates reported an association of H",
"     <sub>",
"      2",
"     </sub>",
"     blocker use and an increased incidence of NEC in VLBW neonates (Guillet, 2006).  An ~sixfold   increase in mortality, NEC, and infection (ie, sepsis, pneumonia, UTI) was reported in patients receiving an H",
"     <sub>",
"      2",
"     </sub>",
"     blocker (ranitidine) in a cohort analysis of 274 VLBW neonates (Terrin, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F151562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (moderate), CYP2C19 (moderate), CYP2C9 (weak), CYP2D6 (moderate), CYP2E1 (weak), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F151481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Cimetidine may increase the serum concentration of Alfentanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Cimetidine may increase the serum concentration of Amiodarone.  Management: Consider alternatives to cimetidine. If this combination cannot be avoided, monitor for increased amiodarone concentrations/effects with cimetidine initiation/dose increase or decreased concentrations/effects with cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Cimetidine may enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Cimetidine may increase the serum concentration of Anticonvulsants (Hydantoin).  Management: Consider using an alternative H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist to avoid this interaction. Monitor for toxic effects of hydantoin anticonvulsants if cimetidine is initiated/dose increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ethotoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: H2-Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Cimetidine may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: H2-Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromazepam: Cimetidine may increase the serum concentration of Bromazepam.  Management: Consider use of bromazepam with an H2-antagonist that is not a potent CYP inhibitor (e.g., ranitidine) or alternatively, consider use of cimetidine with a benzodiazepine that does not undergo oxidative metabolism (e.g., lorazepam).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Cimetidine may increase the serum concentration of Calcium Channel Blockers.  Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AmLODIPine; Clevidipine; NiCARdipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Cimetidine may increase the serum concentration of CarBAMazepine. The serum carbamazepine concentration might return to normal within one week of starting cimetidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carmustine: Cimetidine may enhance the myelosuppressive effect of Carmustine.  Management: Consider alternatives to cimetidine in patients receiving carmustine.  If the combination cannot be avoided, monitor for enhanced carmustine myelotoxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: Cimetidine may increase the serum concentration of Carvedilol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: H2-Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: H2-Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: H2-Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Cimetidine may increase the serum concentration of Cisapride.  Management: Consider alternatives to cimetidine. If this combination cannot be avoided, monitor for toxic effects of cisapride if cimetidine is initiated/dose increased, or decreased efficacy if cimetidine is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Cimetidine may increase the serum concentration of CloZAPine.  Management: Consider use of an alternative H2 antagonist. Monitor for increased toxic effects of clozapine if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: Cimetidine may increase the serum concentration of Dalfampridine.  Management: Recommendations differ significantly between international labelings in regards to the concomitant use of dalfampridine (referred to as fampridine in Canada) and cimetidine. Consult appropriate product labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: H2-Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: H2-Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: H2-Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Cimetidine may increase the serum concentration of Dofetilide. This is likely via inhibition of dofetilide renal tubular secretion (primarily) and inhibition of dofetilide metabolism.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPIrubicin: Cimetidine may increase the serum concentration of EPIrubicin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: H2-Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Escitalopram: Cimetidine may increase the serum concentration of Escitalopram.  Management: Consider using an alternative H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist to avoid the risk of escitalopram toxicity. Escitalopram Canadian product labeling recommends limiting escitalopram dose to 10 mg/day with concomitant use of cimetidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: H2-Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: H2-Antagonists may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: H2-Antagonists may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: H2-Antagonists may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: H2-Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): H2-Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mebendazole: Cimetidine may increase the serum concentration of Mebendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: H2-Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Cimetidine may increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: H2-Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moclobemide: Cimetidine may decrease the metabolism of Moclobemide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): H2-Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: H2-Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nicotine: Cimetidine may increase the serum concentration of Nicotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: H2-Antagonists may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and the H2 receptor antagonist by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: Cimetidine may increase the serum concentration of Pentoxifylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: H2-Antagonists may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: H2-Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use whenever possible.  Monitor patients closely for decreased antifungal effects if this combination is used.  Consider using a noninteracting antifungal as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: Cimetidine may increase the serum concentration of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: Cimetidine may increase the serum concentration of Praziquantel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: Cimetidine may decrease the excretion of Procainamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Cimetidine may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Cimetidine may increase the serum concentration of QuiNIDine.  Management: Consider alternatives to cimetidine. If the combination cannot be avoided, monitor for increased quinidine concentrations/toxicity with cimetidine initiation/dose increase, or decreased concentrations/effects with cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Cimetidine may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: H2-Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: H2-Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: Cimetidine may increase serum concentrations of the active metabolite(s) of Roflumilast. Cimetidine may increase the serum concentration of Roflumilast.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: H2-Antagonists may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Cimetidine may decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cimetidine may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Cimetidine may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Cimetidine may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: H2-Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: H2-Antagonists may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cimetidine may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zaleplon: Cimetidine may decrease the metabolism of Zaleplon.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ZOLMitriptan: Cimetidine may increase the serum concentration of ZOLMitriptan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1057358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit xanthine-containing foods and beverages",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F151484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3338825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies; therefore, cimetidine is classified as pregnancy category B. Cimetidine crosses the placenta. An increased risk of congenital malformations or adverse events in the newborn has generally not been observed following maternal use of cimetidine during pregnancy. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD), as well as gastric and duodenal ulcers during pregnancy. Although if needed, cimetidine is not the agent of choice. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists may be used for aspiration prophylaxis prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, gastric pH, occult blood with GI bleeding; monitor renal function to correct dose",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibition of histamine at H",
"     <sub>",
"      2",
"     </sub>",
"     -receptors of the gastric parietal cells resulting in reduced gastric acid secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; breast milk to plasma ratio: 4.6-11.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 13% to 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic with a sulfoxide as the major metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 60% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 3.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with normal renal function: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 45-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily in urine (48% unchanged drug); some excretion in bile and feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/30/27109?source=see_link\">",
"      see \"Cimetidine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid excessive amount of coffee and aspirin; when self medicating, if symptoms of heartburn, acid indigestion, or sour stomach persist after 2 weeks of continuous use of the drug, consult a clinician; notify your physician if taking other medications (multiple drug interactions exist)",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral solution is available (strength expressed as base: 60 mg/mL)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 60 mg/mL oral suspension may be made with tablets. Place twenty-four 300 mg tablets in 5 mL of sterile water for ~3-5 minutes to dissolve film coating. Crush tablets in a mortar and reduce to a fine powder. Add 10 mL of glycerin and mix to a uniform paste; mix while adding Simple Syrup, NF in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label \"shake well\" and \"refrigerate\". Stable for 17 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Canani RB, Cirillo P, Roggero P, et al, \"Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(5):e817-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/58/43943/abstract-text/16651285 /pubmed\" id=\"16651285 \" target=\"_blank\">",
"        16651285",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guillet R, Stoll BJ, Cotten CM, et al, \"Association of H",
"      <sub>",
"       2",
"      </sub>",
"      -Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(2):137-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/58/43943/abstract-text/16390920/pubmed\" id=\"16390920\" target=\"_blank\">",
"        16390920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lambert J, Mobassaleh M, and Grand RJ, &ldquo;Efficacy of Cimetidine for Gastric Acid Suppression in Pediatric Patients,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 120(3):474-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/58/43943/abstract-text/1538302/pubmed\" id=\"1538302\" target=\"_blank\">",
"        1538302",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lloyd CW, Martin WJ, Taylor BD, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Cimetidine and Metabolites in Critically Ill Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1985, 107(2):295-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/58/43943/abstract-text/4020559/pubmed\" id=\"4020559\" target=\"_blank\">",
"        4020559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lloyd CW, Martin WJ, and Taylor BD, &ldquo;The Pharmacokinetics of Cimetidine and Metabolites in a Neonate,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1985, 19(3):203-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/58/43943/abstract-text/3884305 /pubmed\" id=\"3884305 \" target=\"_blank\">",
"        3884305",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Somogyi A and Gugler R, &ldquo;Clinical Pharmacokinetics of Cimetidine,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(6):463-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/58/43943/abstract-text/6418428 /pubmed\" id=\"6418428 \" target=\"_blank\">",
"        6418428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Terrin G, Passariello A, De Curtis M, et al, \"Ranitidine Is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in Newborns,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2012, 129(1):40-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/58/43943/abstract-text/22157140/pubmed\" id=\"22157140\" target=\"_blank\">",
"        22157140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13156 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-218.28.111.102-5CC63B1F68-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43943=[""].join("\n");
var outline_f42_58_43943=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151515\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151516\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057349\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442255\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057342\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151488\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151472\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057353\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057345\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057352\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151577\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151574\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057356\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057341\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057340\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151562\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151481\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057358\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151484\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3338825\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057348\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057339\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057355\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057347\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806351\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13156\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13156|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=related_link\">",
"      Cimetidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/30/27109?source=related_link\">",
"      Cimetidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_58_43944="ECG Lown-Ganong-Levine syndrome tutorial";
var content_f42_58_43944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1108px;\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) showing Lown-Ganong-Levine syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 152px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This syndrome is characterized by a short PR interval (&lt;0.12 seconds) and a normal QRS complex due to rapid atrioventricular conduction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43944=[""].join("\n");
var outline_f42_58_43944=null;
var title_f42_58_43945="Laboratory evaluation of the immune system";
var content_f42_58_43945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laboratory evaluation of the immune system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/58/43945/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/58/43945/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/58/43945/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/58/43945/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/58/43945/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/58/43945/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/58/43945/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/58/43945/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune deficiency most often comes to clinical attention because of an increase in the incidence or severity of infectious illness beyond what is considered \"normal.\" This topic review will provide a general approach to the laboratory evaluation of the immune system, beginning with screening tests and progressing through the indications for more advanced immunologic testing. Indications for referral to a specialist are discussed, and links to more detailed topics about the different groups of disorders are provided here and throughout the topic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24614?source=see_link\">",
"     \"Laboratory evaluation of neutropenia and neutrophil dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=see_link\">",
"     \"Overview and clinical assessment of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19688153\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune deficiency disorders should be considered once the more common causes of recurrent infection have been excluded. The initial approach to a child or adult with recurrent infections is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43433?source=see_link\">",
"     \"Approach to the adult with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immune dysregulation can result in disorders other than recurrent infections, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune disorders, such as autoimmune hemolytic anemia",
"     </li>",
"     <li>",
"      Inflammatory disorders, such as inflammatory bowel disease or inflammatory arthritis",
"     </li>",
"     <li>",
"      Malignancies, such as lymphoma",
"     </li>",
"     <li>",
"      Allergic disease, such as atopic dermatitis, food allergy, and allergic rhinosinusitis and asthma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Before initiating immunologic testing, the clinician should perform a thorough clinical history and physical examination. In infants and children, height and weight records should be reviewed, as failure to thrive and poor growth are consistent with immunodeficiency. In patients with possible immunodeficiency, important elements of the clinical presentation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nature of the infections: This should include the frequency, chronicity, severity, and response to therapy. Other considerations include what organ system(s) is involved and what type of organism has been identified in the past (ie, viral, bacterial, fungal, opportunistic), since patterns of infections can suggest specific immune defects",
"     </li>",
"     <li>",
"      Age of onset of illness, since different immune problems present in infancy, childhood, and adulthood",
"     </li>",
"     <li>",
"      The patient&rsquo;s sex, because X-linked defects are mostly or exclusively seen in boys",
"     </li>",
"     <li>",
"      Any associated nonimmunologic symptoms and signs, as revealed by a complete review of systems",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3063312\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination findings that suggest immunodeficiency in children and adults are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link&amp;anchor=H21#H21\">",
"     \"Approach to the child with recurrent infections\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43433?source=see_link&amp;anchor=H4545049#H4545049\">",
"     \"Approach to the adult with recurrent infections\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22450775\">",
"    <span class=\"h2\">",
"     Initial screening laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients of any age, the laboratory evaluation of the immune system begins with general studies, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count with differential: Lymphopenia is characteristic of a variety of combined cellular and antibody deficiency immunodeficiencies. Lymphopenia is defined as an absolute lymphocyte count &lt;1500",
"      <span class=\"nowrap\">",
"       cells/microliter",
"      </span>",
"      in adults or &lt;2500",
"      <span class=\"nowrap\">",
"       cells/microliter",
"      </span>",
"      in infants. Neutropenia can be found in primary phagocyte disorders, as well as in neutrophil disorders that lead to secondary immunodeficiency. Leukocytosis is sometimes noted and suggests chronic infection.",
"     </li>",
"     <li>",
"      Chemistry panels to assess for metabolic disorders (diabetes mellitus, renal disease) that might cause secondary immune deficiency. Hypoalbuminemia or low serum proteins suggest malnutrition or protein loss. Markedly elevated globulin levels may be seen in gammopathies or chronic infections.",
"     </li>",
"     <li>",
"      Urinalysis for proteinuria, casts, or cells, which suggest nephritis.",
"     </li>",
"     <li>",
"      Tests to evaluate for specific infections, if indicated by the presentation (eg, appropriate cultures, chest",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sinus imaging): Sinus films may uncover extensive chronic sinusitis in patients with immune deficiency. Children or adolescents with nasal polyposis (although not adults) should be evaluated for cystic fibrosis, which is a cause of frequent sinopulmonary infections. Chest radiographs of an infant showing absence of a thymic shadow should prompt an emergent evaluation for severe forms of immunodeficiency (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67690 \" href=\"mobipreview.htm?28/56/29571\">",
"       image 1",
"      </a>",
"      ). In older children and adults, chest radiographs may show scarring from past infections, interstitial lung disease, or bronchiectasis. Hyperinflated lung fields suggest chronic obstructive lung disease or chronic asthma.",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C-reactive protein: Nonspecific elevations in acute phase reactants can be seen with infectious and inflammatory disorders and suggest the need for further evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22450812\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;More advanced immunologic tests require varying degrees of expertise to perform and interpret, may not be widely available, and are often costly. In addition, knowledge about the possible diagnoses in question is invaluable in deciding the type of testing to pursue first. Thus, immunologic testing is best performed in a graded fashion, and referral to an",
"    <span class=\"nowrap\">",
"     allergist/immunologist",
"    </span>",
"    should be sought early in the process, when possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultimately, definitive diagnosis may require specialized flow cytometric or molecular methods available in reference laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] or some Children's Hospitals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/4\">",
"     4",
"    </a>",
"    ]. The website of the National Library of Medicine has a directory of illnesses and laboratories in which genetic tests are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7642616\">",
"    <span class=\"h1\">",
"     CATEGORIES AND PREVALENCE OF IMMUNE DEFICIENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune deficiency disorders may be grouped into categories based upon the part of the immune system that is predominantly affected. The prevalence of each group of disorders in the population has been estimated to include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibody deficiencies and defects account for approximately 65 percent of identified immunodeficiency disorders",
"     </li>",
"     <li>",
"      Combined antibody and cellular deficiencies: 15 percent",
"     </li>",
"     <li>",
"      Disorders of phagocytes: 10 percent",
"     </li>",
"     <li>",
"      Isolated cellular defects: 5 percent",
"     </li>",
"     <li>",
"      Disorders of the complement system: 5 percent",
"     </li>",
"     <li>",
"      Other disorders of innate immunity: &lt;1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these categories of disorders has characteristic clinical manifestations, although there are varying degrees of overlap among the clinical presentations of the groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22451541\">",
"    <span class=\"h1\">",
"     OVERVIEW OF CLINICAL MANIFESTATIONS AND TESTING FOR SPECIFIC COMPONENTS OF THE IMMUNE SYSTEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17005404\">",
"    <span class=\"h2\">",
"     Antibody deficiency and defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody deficiency most frequently results in recurrent and severe sinopulmonary infections with encapsulated bacterial strains (eg, Streptococcus pneumoniae, Haemophilus influenzae). Children commonly present with recurrent otitis media, sinusitis, and pneumonia. Adults present similarly, although otitis media is less common. Viral infections of the respiratory tract also occur with greater frequency and severity in these patients. Clinical presentation is discussed in more detail elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The age of the patient can help narrow the differential diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common antibody defects that present in",
"      <strong>",
"       infancy",
"      </strong>",
"      are transient hypogammaglobulinemia of infancy, selective antibody deficiency (after the age of two years) and selective IgA deficiency.",
"     </li>",
"     <li>",
"      The most common antibody deficiencies in",
"      <strong>",
"       young children",
"      </strong>",
"      are selective antibody deficiency, selective IgA deficiency, IgG subclass deficiency, and early-onset common variable immunodeficiency.",
"     </li>",
"     <li>",
"      The most common disorders that present in",
"      <strong>",
"       adulthood",
"      </strong>",
"      include common variable immunodeficiency, selective IgA deficiency, IgG subclass deficiency, and selective antibody deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The disorders mentioned above are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/36/41544?source=see_link\">",
"     \"Transient hypogammaglobulinemia of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17209?source=see_link\">",
"     \"Selective antibody deficiency with normal immunoglobulins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24570?source=see_link\">",
"     \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13258?source=see_link\">",
"     \"IgG subclass deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/45/38617?source=see_link\">",
"     \"Common variable immunodeficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19688885\">",
"    <span class=\"h3\">",
"     Measurement of antibody levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of immunoglobulin G (IgG), IgA, and IgM is useful in all cases of suspected antibody deficiency.",
"   </p>",
"   <p>",
"    There are several methods for determining serum Ig levels, and laboratories use different systems. Therefore, it is critical that age-adjusted normal reference ranges are provided. Hypogammaglobulinemia is defined as an IgG less than two standard deviations from normal, and agammaglobulinemia is usually considered when IgG is &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Panhypogammaglobulinemia (ie, low levels of IgA, IgG, and IgM) is a hallmark of most forms of severe combined immune deficiency. In other combined immune deficiencies, as well as in several predominantly humoral immune deficiencies, there are characteristic alterations in the profile of immunoglobulin (Ig) isotypes that may aid in diagnosis (eg, selective IgA deficiency, selective IgM deficiency, and hyper IgM immunodeficiencies).",
"   </p>",
"   <p>",
"    In addition to IgG, IgA, and IgM, measurement of IgG subclasses and IgE may be useful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of IgG subclasses may be valuable in children older than one year of age and in adults, particularly if the IgG level is borderline low",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      there is a weak or absent antibody response to vaccination. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13258?source=see_link\">",
"       \"IgG subclass deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measurement of IgE is helpful in patients with recurrent sinopulmonary infections, as an elevation is consistent with underlying allergic disease. A very elevated IgE (ie, &gt;2000",
"      <span class=\"nowrap\">",
"       IU/mL)",
"      </span>",
"      in a patient with recurrent bacterial infections and dermatitis would raise suspicion for hyperimmunoglobulin E syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32153?source=see_link\">",
"       \"Hyperimmunoglobulin E syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measurement of serum IgD is",
"    <strong>",
"     not",
"    </strong>",
"    useful for the diagnosis of immune deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19688892\">",
"    <span class=\"h3\">",
"     Measurement of antibody function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody function can be assessed by measuring antibody titers (usually IgG) to specific organisms (aka specific antibody) in response to intentional immunization or natural infection. Antibody function is critical for determining the integrity of humoral immunity for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinically significant impairment in antibody function can be present even when serum antibody levels are normal. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17209?source=see_link\">",
"       \"Selective antibody deficiency with normal immunoglobulins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Normal responses to immunization (ie, normal antibody function) can occur with subnormal levels of total IgG or of IgG subclasses. This pattern is typically seen with secondary causes of hypogammaglobulinemia, such as that caused by medications, protein loss, or severe malnutrition. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7561?source=see_link\">",
"       \"Secondary immune deficiency due to miscellaneous causes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29706?source=see_link\">",
"       \"Secondary immune deficiency induced by drugs and biologics\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antibody function is assessed by examining the patient&rsquo;s response to the two general types of antigens; protein antigens and polysaccharide antigens. Routine vaccinations provide examples of both types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of antibody titers to tetanus, diphtheria, Hemophilus influenzae B, and protein-conjugated pneumococcal vaccines (eg, Prevnar&reg;) are used to assess response to protein antigens. Antibody titers to other vaccines (eg, hepatitis A and hepatitis B, measles, others) can also be used.",
"     </li>",
"     <li>",
"      Measurement of antibody titers to multiple serotypes in pneumococcal polysaccharide vaccines (Pneumovax 23&reg;, Merck; Pnu-imune 23&reg;, Lederle) are used to assess response to polysaccharide antigens. This evaluation is useful in adults and children older than two years. This response is particularly important in making a diagnosis of selective antibody deficiency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17209?source=see_link\">",
"       \"Selective antibody deficiency with normal immunoglobulins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Isohemagglutinins are antibodies generated in response to polysaccharides of gut flora and which cross-react with A or B blood group erythrocyte antigens. They generally appear in the blood by six months of age in individuals who have blood types",
"      <strong>",
"       other than",
"      </strong>",
"      AB. However, vaccine responsiveness is generally considered to be a more reliable indicator of intact humoral immune function. Isohemagglutinin testing is reviewed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24328?source=see_link&amp;anchor=H19#H19\">",
"       \"Assessing the immunologic response to vaccination\", section on 'Isohemagglutinin testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assessing vaccine responses is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H183845940\">",
"    <span class=\"h2\">",
"     Measurement of immune globulin loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low levels of immunoglobulins are occasionally due to loss of immune globulin into the GI tract, urine, lung, skin, or peritoneal fluid during dialysis in patients with certain chronic diseases. A method of evaluating the rate of IgG loss is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7561?source=see_link&amp;anchor=H16802278#H16802278\">",
"     \"Secondary immune deficiency due to miscellaneous causes\", section on 'Disorders of protein loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Defects in cellular immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific cellular immunity is mediated by T cells, and defects affecting these T cells underlie the most severe immune deficiencies. However, because antibody production by B cells requires intact T cell function, most T cell defects lead to combined (cellular and humoral) immune deficiency.",
"   </p>",
"   <p>",
"    An evaluation of cellular immunity is appropriate for patients with severe viral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacterial illnesses or opportunistic infections. The disorders that can impair cellular immunity are different in various age groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children younger than one year of age, primary immunodeficiencies are the most common cause of impaired cellular immunity, although perinatal cytomegalovirus and other herpes virus infections can cause transient or persistent cellular immunodeficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In older children and adults, the major causes are HIV infection and iatrogenic immune suppression due to therapy for autoimmune disease, malignancy, or transplantation. Occasionally, mild forms of primary combined immune deficiency or DiGeorge syndrome escape diagnosis until adolescence or adulthood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most profound combined immunodeficiencies are classified under the heading &ldquo;severe combined immunodeficiency&rdquo; or SCID. SCID disorders usually present in infancy, while less severe combined immunodeficiencies present in children and occasionally, in adolescents or adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Complete blood count with differential and blood smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complete blood count (CBC) with differential and blood smear provides valuable information about the cellular immune system. Normal lymphocyte counts in infants are much higher than in older children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In many primary immunodeficiency disorders, cell populations are initially normal, and then decline over time. Thus, normal results in the past cannot be relied upon as a reflection of the current state.",
"   </p>",
"   <p>",
"    In patients suspected of having a defect in cellular immunity, the CBC establishes the presence or absence of lymphopenia and any associated gross hematologic abnormalities, some of which may greatly assist in diagnosis. A single finding of lymphopenia should be interpreted with caution, since transient lymphopenia is frequently found in a variety of common infectious illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/11\">",
"     11",
"    </a>",
"    ]. However, significant lymphopenia that does not rapidly correct should not be ignored, since lymphopenia may be the first indication of cellular immunodeficiency or another serious disease (eg, lymphoma) (",
"    <a class=\"graphic graphic_table graphicRef58469 \" href=\"mobipreview.htm?8/2/8236\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/12\">",
"     12",
"    </a>",
"    ]. In rare situations, a normal lymphocyte count can be seen in the presence of a severe immunodeficiency. If the clinical presentation is highly suggestive of an underlying disorder (eg, a patient with Pneumocystis pneumonia and invasive candida), then lymphocyte subsets should be evaluated with flow cytometry even if the total lymphocyte count is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H674032\">",
"    <span class=\"h4\">",
"     Evaluation of lymphopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphopenia can be caused by an array of disorders (",
"    <a class=\"graphic graphic_table graphicRef58469 \" href=\"mobipreview.htm?8/2/8236\">",
"     table 1",
"    </a>",
"    ). Flow cytometry to evaluate lymphocyte populations should be performed in all patients suspected of cellular immunodeficiency with any significant infection and a total lymphocyte count &lt;1500",
"    <span class=\"nowrap\">",
"     cells/microliter",
"    </span>",
"    (&lt;2500",
"    <span class=\"nowrap\">",
"     cells/microliter",
"    </span>",
"    in infants). In the absence of other indicators of immune dysfunction, there should at the very least be subsequent measurement of the lymphocyte count to document normalization. Persistent lymphopenia requires further investigation of immune function. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Flow cytometry'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14668033\">",
"    <span class=\"h3\">",
"     Cutaneous delayed-type hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous delayed-type hypersensitivity (DTH) is the classic in vivo test of cellular immunity. This test measures the recall response to an intradermal injection of an antigen to which an individual has already been exposed over a period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/13\">",
"     13",
"    </a>",
"    ]. For that reason skin testing is usually not of much value under age two.",
"   </p>",
"   <p>",
"    A positive response to intracutaneous antigen injection requires uptake and processing of antigen by antigen presenting cells, their interaction with CD4+ helper T cells, cytokine production by T cells, and subsequent recruitment and activation of monocytes and macrophages. Thus, skin testing is a sensitive indicator of intact cellular immunity, but negative results must be interpreted with caution, because an impairment in any step of the response pathway will lead to a negative response. In addition, the DTH response is unreliable in children under one year of age (even with prior antigen exposure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/14\">",
"     14",
"    </a>",
"    ], and is often suppressed during viral and bacterial infection (even with live attenuated vaccines as in the combined measles, mumps, and rubella vaccine). DTH skin reactivity is also suppressed by antiinflammatory drugs (glucocorticoids) and other immunosuppressants (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , mycophenolic acid). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29706?source=see_link\">",
"     \"Secondary immune deficiency induced by drugs and biologics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14668060\">",
"    <span class=\"h4\">",
"     Method",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed hypersensitivity skin responses can be assessed using an intradermal injection of Candida antigen (Candin&reg;, Allermed Laboratories). This is the only commercially-available reagent intended for use in DTH testing. A 0.1 mL dose of undiluted Candin&reg; is injected intradermally in the volar surface of the forearm. The response is measured 48 to 72 hours after injection. Induration of more than 5 mm is considered positive in all cases. In children, induration of more than 2 mm is sometimes accepted as positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/15\">",
"     15",
"    </a>",
"    ]. Erythema alone does not indicate a positive reaction.",
"   </p>",
"   <p>",
"    In one author&rsquo;s center (ERS), a panel of four reagents is used for DTH testing: Candin&reg; (as above), Tetanus toxoid (10 flocculation",
"    <span class=\"nowrap\">",
"     units/mL,",
"    </span>",
"    Sanofi Pasteur, diluted to 1.5",
"    <span class=\"nowrap\">",
"     LF/mL),",
"    </span>",
"    PPD (5",
"    <span class=\"nowrap\">",
"     TU/mL,",
"    </span>",
"    Sanofi Pasteur), and Trichophyton (1:500",
"    <span class=\"nowrap\">",
"     w/v,",
"    </span>",
"    Allermed Laboratories).",
"   </p>",
"   <p>",
"    The main advantages of DTH testing are its ease and economy; it is a useful screening test in many instances of suspected cellular immune deficiency. A negative DTH should be followed either with repeated testing (often following a tetanus toxoid booster immunization if tetanus was among the testing reagents), or with measurement of lymphocyte populations by flow cytometry, combined with in vitro assays of T cell function, as discussed below. In vitro assays (particularly mitogen stimulation) are less sensitive to interference during intercurrent illnesses or by drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Flow cytometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flow cytometry uses monoclonal antibodies to identify and quantitate hematopoietic cells that have specific antigens termed cluster designations (CDs). The table lists the fundamental set of markers commonly used and the lymphocyte populations they define (",
"    <a class=\"graphic graphic_table graphicRef78061 \" href=\"mobipreview.htm?31/10/31915\">",
"     table 2",
"    </a>",
"    ). A typical panel of markers used to identify the major subset of lymphocytes includes CD3, CD4, CD8,",
"    <span class=\"nowrap\">",
"     C19/20,",
"    </span>",
"    <span class=\"nowrap\">",
"     CD16/56/57.",
"    </span>",
"    The nature and derivation of the nomenclature of the markers are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A CBC with differential should be performed on a blood specimen obtained at the time of the flow cytometric analysis, or the cytometer itself be used to determine the lymphocyte number. This analysis permits the calculation of the absolute numbers of each lymphocyte subset. It is possible for the percentage of a particular subset to be abnormal while the total number of cells is within the normal range, and vice-versa. An absolute deficiency, rather than a relative (percentage) deficiency, is of much greater clinical significance.",
"   </p>",
"   <p>",
"    Flow cytometry is invaluable in the assessment of lymphocyte subpopulations in patients with opportunistic infections or severe or persistent lymphopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/15\">",
"     15",
"    </a>",
"    ]. Standard flow cytometry analysis will be abnormal in almost all cases of severe combined immune deficiency (SCID), and in many instances of other combined immunodeficiencies (",
"    <a class=\"graphic graphic_table graphicRef65266 \" href=\"mobipreview.htm?33/4/33869\">",
"     table 3",
"    </a>",
"    ). The analysis of lymphocyte subsets may be diagnostic for various forms of lymphoma as well. The use of flow cytometry in the diagnosis of specific immunodeficiencies is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=see_link\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3063384\">",
"    <span class=\"h4\">",
"     Abnormalities in immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The table summarizes anticipated alterations in the representations of various lymphocyte populations in several immune deficiency diseases (",
"    <a class=\"graphic graphic_table graphicRef65266 \" href=\"mobipreview.htm?33/4/33869\">",
"     table 3",
"    </a>",
"    ). Specific disorders are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While certain immune defects are associated with characteristic patterns of lymphocyte subsets, lymphocyte populations may appear to be entirely normal even with clinical evidence of significant immune dysfunction. Conversely, as with total lymphocyte numbers, lymphocyte subsets may be profoundly altered by common infectious illnesses and other factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Thus, for the purpose of diagnosis, flow cytometry data must be considered in conjunction with functional tests of the immune system.",
"   </p>",
"   <p>",
"    Decreased numbers or absent natural killer",
"    <span class=\"nowrap\">",
"     CD16/56",
"    </span>",
"    cells (&le;100",
"    <span class=\"nowrap\">",
"     cells/ul),",
"    </span>",
"    particularly in the presence of recurrent infection with herpes viruses, should warrant further studies for natural killer cell deficiencies, including cytotoxicity studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30889?source=see_link\">",
"     \"NK cell deficiency syndromes: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4354648\">",
"    <span class=\"h3\">",
"     Advanced tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many advanced tests are available to study specific cellular immune defects. These tests are best ordered and interpreted by an immunology expert. Advanced tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advanced flow cytometry using monoclonal antibodies specific for activated cells, regulatory T cells, na&iuml;ve or memory cells, or various stages of B cell development are of value in further characterizing many antibody deficiencies (eg common variable immunodeficiency) or cellular immunodeficiencies (eg immune dysregulation, polyendocrinopathy, enteropathy, X-linked or IPEX syndrome). Flow cytometry can be used in the definitive diagnosis of several genetic immunodeficiencies by assessing the absence or abnormal expression of a specific protein (eg, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=see_link\">",
"       \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Analysis of T cell receptor excision circles (TRECs) provides an assessment of thymic function by measuring recent thymic emigrant cells. This is also used as a screening test for newborn SCID on newborn blood samples. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link&amp;anchor=H6#H6\">",
"       \"Severe combined immunodeficiency (SCID): An overview\", section on 'Newborn screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cytotoxicity assays measure the functional capacity of cytotoxic T cells or natural killer cells. T cell cytotoxicity is a research tool since the target cells must share HLA antigens with the patient. One such method utilizes antigenic peptides attached to specific MHC molecules labeled with a fluorochrome as targets. Binding of the cytotoxic cell to the peptide is measured by flow cytometry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30889?source=see_link&amp;anchor=H15#H15\">",
"       \"NK cell deficiency syndromes: Clinical manifestations and diagnosis\", section on 'Laboratory testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cytokine measurements on cells, serum, or tissue sections.",
"     </li>",
"     <li>",
"      Mutation analysis to identify mutated genes for many T cell or combined defects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/1,5-7\">",
"       1,5-7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chromosome analysis is of value in the diagnosis of DiGeorge syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/12/22729?source=see_link&amp;anchor=H1431580#H1431580\">",
"       \"DiGeorge syndrome: Clinical features and diagnosis\", section on 'Genetic analysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HLA typing is used to identify chimerism in newborns with SCID or to identify an appropriate stem cell donor.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       CD3/T",
"      </span>",
"      cell receptor analysis and function. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28329?source=see_link\">",
"       \"CD3/T cell receptor complex disorders causing immunodeficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     In vitro studies of T cell function",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies of T cell function measure peripheral blood T cell proliferation in response to several different types of stimuli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitogens (such as the plant lectins phytohemagglutinin, concanavalin A, pokeweed mitogen, anti-CD3)",
"     </li>",
"     <li>",
"      Specific antigens (such as tetanus and diphtheria toxoids or C. albicans antigens)",
"     </li>",
"     <li>",
"      Allogeneic lymphocytes (ie, mixed lymphocyte culture)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies may not be possible in patients with profound lymphopenia. In parallel with (or prior to) studies of T cell function, flow cytometric measurement of peripheral blood lymphocyte subpopulations should be performed. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Flow cytometry'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In T cell function studies, the patient's purified peripheral blood mononuclear cells (lymphocytes and monocytes) are incubated in sterile media with the test substance(s) or cells for three to six days. A control tube with cells and media alone is also incubated. During the last 24 hours of culture, tritiated thymidine is added to the cultures. Dividing lymphocytes incorporate the thymidine into their DNA. The extent of proliferation is determined by measuring the radioactivity taken up by cells. The test is interpreted as negative, partial, or normal by comparing patient results with normal control lymphocytes assayed simultaneously and with the normal ranges for controls in the laboratory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many laboratories also report results as a stimulation index (SI). This is the ratio of radioactivity (as counts per minute, or CPM) with stimulation over the CPM in the control tube without stimulation (background).",
"   </p>",
"   <p>",
"    Suppression of T cell responses to mitogens and antigens may be seen with significant nutritional deficiencies, moderate to severe concurrent illnesses, or with administration of immunosuppressive drugs. Thus, these tests should be performed when the patient is relatively well and not receiving glucocorticoids or other immunosuppressive medications, whenever possible. T cell responses appear to normalize rapidly (ie, within a day or two) after glucocorticoids are discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Response to mitogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most mitogens require functional antigen presenting cells (ie, monocytes and B cells) for T cell stimulation, although the mechanisms of antigen processing and presentation are bypassed. Mitogens are powerful stimulants for T cells, and responses may be assessed in patients of any age, even newborns, regardless of immunization status.",
"   </p>",
"   <p>",
"    Normal reference ranges are derived from studies on the cells of healthy adults. Newborns generally have higher mitogen responses compared to adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/19\">",
"     19",
"    </a>",
"    ]. Depending upon the mitogens and the laboratory, the range of counts per minute (CPM) reported for normal controls is approximately 50,000 to 300,000 and SI between 10 and 200. Phytohemagglutinin (PHA) is most commonly used. Results for patients in comparison to controls are roughly interpreted as normal (&gt;50 percent of control), low (25 to 50 percent), very low (10 to 25 percent), or absent (&lt;10 percent). Results expressed as SI vary widely between laboratories. In general, a SI &lt;10 may be considered as no response.",
"   </p>",
"   <p>",
"    Some researchers have also used in vitro stimulation with the OKT3 monoclonal antibody as a measure of T cell function. OKT3 binds to the epsilon chain of the T cell CD3 complex and stimulates T cells (in the presence of accessory or antigen presenting cells) in a manner analogous to T cell mitogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/20\">",
"     20",
"    </a>",
"    ]. Cell response to mitogen or OKT3 is generally similar, although they may sometimes give different patterns in the context of distinct immune defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/21\">",
"     21",
"    </a>",
"    ]. There are no published comparisons in a large group of normal individuals or immune deficient patients. Most clinical reference laboratories use one or more mitogens and one or more antigens, but do not routinely use OKT3.",
"   </p>",
"   <p>",
"    Diminished or absent proliferation signals a serious derangement of T cell function. Mitogen responses will be severely depressed (usually well below the control fifth percentile) in the vast majority of patients with profound lymphopenia (eg, complete DiGeorge syndrome), severe combined immune deficiency (SCID) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/22\">",
"     22",
"    </a>",
"    ], or advanced AIDS. By comparison, the response may be partial or normal in milder syndromes of combined deficiency (eg, Wiskott-Aldrich syndrome), in mainly humoral deficiency, or in those with infections (especially CMV and other herpes viruses) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Response to specific antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific antigen tests are more sensitive than mitogen assays as indicators of defects in T cell function, since the mechanisms of activation are more complex than those for mitogens. These tests require antigen processing and presentation by antigen presenting cells, although T cell recruitment of effector cells (eg, in vivo DTH) is not necessary. As with DTH, in vitro specific antigen proliferation tests are not useful in infants or other patients who have not completed a primary series of immunizations.",
"   </p>",
"   <p>",
"    Tetanus and diphtheria toxoids and monilia (Candida) are antigens frequently used for this assay. Since only a small number of cells respond, the cultures must be maintained longer, and incorporation of radioactivity is lower than for mitogen stimulation. Results expressed as CPM are often reported from 5000 to 50,000; results as SI generally range from 43 to 50. Because of the very large variation in the frequency of antigen-specific T cells in the blood of healthy controls, the SI is often most important for interpretation. In general, a SI for specific antigen &gt;43 is considered adequate.",
"   </p>",
"   <p>",
"    In many cases of combined immune deficiency, responses to specific antigens are diminished or even absent while mitogen responses remain intact. In secondary immune deficiency, specific antigen responses will also generally be suppressed more easily than mitogen responses. However, these generalizations are not always true [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/24\">",
"     24",
"    </a>",
"    ]. As with DTH testing, booster immunization with tetanus followed by a repeat in vitro proliferation assay may detect a significant response.",
"   </p>",
"   <p>",
"    Another way to assess function of T cells is to measure cytokine release following antigen exposure. An example of this type of test that has become widely used in the diagnosis of latent tuberculosis infection is the interferon release assay, which can be used instead of tuberculin testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5551356\">",
"    <span class=\"h2\">",
"     Neutrophil defects (defects in phagocyte function)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophil defects result in a range of illness from mild recurrent skin infections to overwhelming, fatal systemic infection. Affected patients are more susceptible to bacterial and fungal infections, but have a normal resistance to viral infections. Most are diagnosed in infancy due to the severity of the infection or the unusual presentation of the organism, but some escape diagnosis until adulthood.",
"   </p>",
"   <p>",
"    Primary phagocytic deficiencies characteristically lead to recurrent and severe fungal (eg, Candida and Aspergillus) and bacterial (eg, Staphylococcus aureus, Pseudomonas aeruginosa, Nocardia asteroides, Salmonella typhi) infections. Response to nontuberculous mycobacteria may also be abnormal, particularly in patients with chronic granulomatous disease. The most common sites of infection are the respiratory tract and skin. Tissue and organ abscesses also occur. Other frequent manifestations include abnormal wound healing,",
"    <span class=\"nowrap\">",
"     dermatitis/eczema,",
"    </span>",
"    stomatitis, and delayed umbilical cord detachment. Many patients have growth failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Phagocytic disorders can be caused by extrinsic or intrinsic defects. Extrinsic defects include opsonic abnormalities secondary to deficiencies of antibody and complement factors, suppression of granulocyte production, and leukocyte autoantibodies or isoantibodies that decrease the number of circulating neutrophils. Intrinsic disorders of granulocytes may be divided into defects in granulocyte killing ability and defects in chemotaxis (cell movement).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1470308\">",
"    <span class=\"h3\">",
"     Evaluation of neutrophil numbers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial test for evaluation of phagocyte disorders in the CBC with differential:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukocytosis raises the possibility of a leukocyte adhesion defect (ie, a defect in chemotaxis), and flow cytometry is indicated next to assess for the presence of specific adhesion molecules. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22953?source=see_link\">",
"       \"Leukocyte adhesion deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe neutropenia can be seen with congenital agranulocytosis or cyclic neutropenia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24614?source=see_link\">",
"       \"Laboratory evaluation of neutropenia and neutrophil dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If neutrophil numbers are normal and the patient&rsquo;s history is consistent with a neutrophil disorder, then an evaluation of neutrophil function is appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14668477\">",
"    <span class=\"h3\">",
"     Evaluation of neutrophil function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of neutrophil function include chronic granulomatous disease (CGD), Chediak-Higashi syndrome, neutrophil-specific granule deficiency, leukocyte adhesion defects, and hyper IgE syndrome. Initial tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutrophil oxidative burst is best measured by a flow cytometric assay of dihydrorhodamine (DHR). This test is quantitative and is useful in the identification of heterozygote carriers of CGD. This procedure is widely available in reference laboratories and has generally replaced the nitroblue tetrazolium test (NBT test). However the NBT test can be used for screening purposes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=see_link\">",
"       \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10826?source=see_link\">",
"       \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An IgE level, which is often elevated in hyper IgE syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32153?source=see_link\">",
"       \"Hyperimmunoglobulin E syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Examination of a peripheral blood smear to detect:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The giant azurophilic granules in neutrophils, eosinophils, and other granulocytes (",
"      <a class=\"graphic graphic_picture graphicRef57556 \" href=\"mobipreview.htm?25/52/26436\">",
"       picture 1",
"      </a>",
"      ), which are diagnostic of Chediak-Higashi syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42278?source=see_link\">",
"       \"Chediak-Higashi syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neutrophils that lack granules and are often bilobed, which are found in neutrophil-specific granule deficiency (",
"      <a class=\"graphic graphic_picture graphicRef71996 \" href=\"mobipreview.htm?8/13/8400\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10838?source=see_link\">",
"       \"Neutrophil-specific granule deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advanced mutation analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/5-7\">",
"       5-7",
"      </a>",
"      ] and flow cytometric analysis for many neutrophil disorders are also available. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=see_link\">",
"       \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A chemotaxis assay can be done to identify a cell movement disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5551391\">",
"    <span class=\"h2\">",
"     Complement defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement disorders may be inherited or acquired. Screening for a classical complement pathway defect is indicated in patients with any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent, unexplained pyogenic infections in whom the white blood count and immunoglobulin levels and specific antibody responses are normal",
"     </li>",
"     <li>",
"      Recurrent Neisserial infections at any age",
"     </li>",
"     <li>",
"      Multiple family members who have experienced Neisserial infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, it is reasonable to evaluate the complement system in any patient with systemic lupus erythematosus (SLE). However, this is particularly relevant in those with familial lupus or subacute cutaneous lupus, in whom C1q or C2 deficiency should be excluded.",
"   </p>",
"   <p>",
"    The initial screening test for complement defects is a total hemolytic complement assay (CH50), which assesses classical pathway function and is widely available. If the CH50 is significantly reduced or zero, then the levels of individual complement components are measured. Low levels of multiple components, particularly low C3 and C4, suggest complement consumption, rather than a primary complement deficiency. If the CH50 is normal and a complement defect is still suspected, the AH50, a screening test for alternative pathway defects, may be obtained. This test is largely performed in specialized laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/25\">",
"     25",
"    </a>",
"    ]. Alternative complement deficiencies include properdin and factor D deficiencies, both of which are rare. Inherited and acquired defects in complement components are reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29542?source=see_link\">",
"     \"Acquired disorders of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a patient has frequent infections suggestive of a complement deficiency, a mannose-binding lectin defect should be excluded. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/14/19690?source=see_link\">",
"     \"Mannose-binding lectin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Defects and deficiencies of C1 esterase inhibitor are associated with hereditary angioedema, although these disorders are not immunodeficiencies because these patients do not have increased susceptibility to infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4354744\">",
"    <span class=\"h2\">",
"     Innate immune defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in innate immune mechanisms are relatively rare disorders that should be suspected in patients in which other immunodeficiencies have been excluded. Many are associated with specific infections (eg, herpes or EBV infections in NK cell defects, atypical mycobacterial infection in",
"    <span class=\"nowrap\">",
"     IL-12/23-IFN-&gamma;",
"    </span>",
"    pathway defects, neonatal herpes simplex encephalitis in the TLR-3 signaling pathway and other severe infections, often associated with poor inflammatory response).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4354757\">",
"    <span class=\"h3\">",
"     Natural killer cell defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK cell defect can be primary or secondary. Primary NK deficiency should be suspected in patients with low NK cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent severe herpes virus infections. NK defects are also noted in patients with X-linked lymphoproliferative disorders and Hemophagocytic lymphohistiocytosis, Chediak-Higashi syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30889?source=see_link&amp;anchor=H15#H15\">",
"     \"NK cell deficiency syndromes: Clinical manifestations and diagnosis\", section on 'Laboratory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H137261\">",
"    <span class=\"h3\">",
"     Defects of IL-12/23-IFN-gamma pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with invasive infections caused by low virulence Mycobacterial and Salmonella species may have defects of the genetic components of the",
"    <span class=\"nowrap\">",
"     IL-12/23-IFN-&gamma;",
"    </span>",
"    pathways including the IFN-&gamma; receptor 1 gene (IFNGR1) or the IFN-&gamma; receptor 2 gene (IFNGR2), the IL-12 receptor &beta;1 gene (IL12RB1), the IL12B gene, and the STAT1 gene. Special tests involving western blotting or flow cytometry can pinpoint the exact molecular defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=see_link\">",
"     \"Mendelian susceptibility to mycobacterial diseases (MSMD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4354769\">",
"    <span class=\"h3\">",
"     Toll-like receptor pathway defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pattern recognition receptors (PRRs) are receptors specific for molecular components of microorganisms widely expressed on phagocytic cells (neutrophils, macrophages, and monocytes and several other cells). Defects in PRRs can cause increased susceptibility to infections that is most severe in infancy, before the adaptive (ie, humoral and cellular) immune system has developed. The frequency and severity of infections generally lessen as the patient matures, in contrast to most other types of immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16986?source=see_link\">",
"     \"An overview of the innate immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Toll-like receptors (TLRs) are one group of PRRs that, after ligation with specific microorganisms, initiate a series of steps that eventually activate the nucleus to initiate cytokine synthesis. Several genetic disorders of the signaling pathways have been identified, including an IL-1 receptor-associated kinase 4 defect (IRAK4), a myeloid differentiation primary response gene 88 defect (MYD88), a nuclear factor kappa B essential modulator defect (NEMO), a TLR3 receptor defect, and an UNC-93B defect. Screening tests to evaluate these defects are available, including a flow cytometric assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/58/43945/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23401?source=see_link&amp;anchor=H20#H20\">",
"     \"Toll-like receptors: Roles in disease and therapy\", section on 'Primary immunodeficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=see_link\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H674024\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune deficiency disorders should be considered once the more common causes of recurrent infection have been excluded. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link\">",
"       \"Approach to the child with recurrent infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43433?source=see_link\">",
"       \"Approach to the adult with recurrent infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Before initiating immunologic testing, the clinician should perform a thorough clinical history and physical examination. In infants and children, height and weight records should be reviewed to detect failure to thrive and poor growth. Routine laboratories can provide clues about other causes of infections and help focus further immunologic evaluation. Screening laboratories include complete blood count with differential, chemistry panels, urinalysis, test to diagnose specific organ involvement (eg, sinus CT or chest radiograph), and CRP or ESR to look for elevations that may accompany chronic infections. (See",
"      <a class=\"local\" href=\"#H19688153\">",
"       'Initial approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunologic testing is best performed in a graded fashion, and referral to an",
"      <span class=\"nowrap\">",
"       allergist/immunologist",
"      </span>",
"      should be sought early in the process, when possible, because many tests require varying degrees of expertise to perform and interpret, may not be widely available, and are often costly. (See",
"      <a class=\"local\" href=\"#H22450812\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Defects in humoral immunity, which account for about 65 percent of primary immunodeficiencies, usually result in recurrent and severe sinopulmonary infections with encapsulated bacterial strains. IgG, IgA, and IgM should be measured initially. The next step in evaluation is the measurement of serum specific antibody titers (IgG) in response to intentional immunization (vaccine response) or natural infection. (See",
"      <a class=\"local\" href=\"#H17005404\">",
"       'Antibody deficiency and defects'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24328?source=see_link\">",
"       \"Assessing the immunologic response to vaccination\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Defects in cellular immune function (T cell disorders) are often accompanied by antibody defects, yielding combined immunodeficiencies. Isolated cellular defects and combined defects together account for about 20 percent of primary immunodeficiencies. These disorders should be considered in any child presenting with recurrent or severe viral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bacterial illnesses or opportunistic infections in the first year of life. Presentation in adulthood is uncommon, although it does occur. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Defects in cellular immunity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lymphopenia is an early indicator of severe combined immunodeficiency (SCID) in infants and of combined immunodeficiencies in older children and occasionally adults. This should be followed by flow cytometry to determine which lymphocyte subsets are deficient (",
"      <a class=\"graphic graphic_table graphicRef78061 \" href=\"mobipreview.htm?31/10/31915\">",
"       table 2",
"      </a>",
"      ) . In most cases, the evaluation should be repeated at several points in time, as viral infections and other factors can influence lymphocyte counts. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Complete blood count with differential and blood smear'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H674032\">",
"       'Evaluation of lymphopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An overview of the anticipated alterations in various lymphocyte populations observed in several immune deficiency diseases is provided (",
"      <a class=\"graphic graphic_table graphicRef65266 \" href=\"mobipreview.htm?33/4/33869\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3063384\">",
"       'Abnormalities in immunodeficiency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=see_link\">",
"       \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cutaneous delayed-type hypersensitivity (DTH) testing is a sensitive indicator of intact cellular immunity, because a normal recall response to an antigen requires that multiple cell types and cellular interactions are functional. For these reasons, DTH testing can be used as a simple and economical means to exclude a defect in cellular immunity in adults and older children. However, negative results must be interpreted with caution, because there are multiple reasons for nonresponse. (See",
"      <a class=\"local\" href=\"#H14668033\">",
"       'Cutaneous delayed-type hypersensitivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In vitro studies of T cell function measure peripheral blood T cell proliferation in response to mitogens or antigens. Mitogen responses may be assessed in patients of any age, regardless of immunization status. Specific antigen tests are only useful in patients who have been previously immunized to that antigen, but may be more sensitive than mitogen assays as indicators of defects in T cell function. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'In vitro studies of T cell function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Advanced tests for T cell deficiencies may include cytokine release assays and cytotoxic assays using HLA-matched target cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary phagocytic cell deficiencies, which account for about 10 percent of primary immunodeficiencies, characteristically lead to recurrent and severe fungal (eg, Candida and Aspergillus) and bacterial infections. The most common sites of infection are the respiratory tract and skin, but deep tissue and organ abscesses are also seen. Initial testing for these disorders is the complete blood count with differential, followed by various specific tests of phagocyte function, depending upon the disorder suspected. (See",
"      <a class=\"local\" href=\"#H5551356\">",
"       'Neutrophil defects (defects in phagocyte function)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complement defects should be considered in patients with recurrent pyogenic infections with normal white blood cell counts and immunoglobulins, and in patients with a personal or family history of recurrent neisserial infections. A total hemolytic complement (CH50) is the initial screening test. (See",
"      <a class=\"local\" href=\"#H5551391\">",
"       'Complement defects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Defects in innate immune mechanisms are rare disorders that should be suspected in patients with recurrent infections, often of a specific type (eg, herpes viruses), in which other immunodeficiencies have been excluded. (See",
"      <a class=\"local\" href=\"#H4354744\">",
"       'Innate immune defects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Library of Medicine compilation of sites for specific Gene Testing. file://ncbi.nih.gov/sites/GeneTests/review.",
"    </li>",
"    <li>",
"     GeneDX: www.genedx.com (Accessed on June 02, 2011).",
"    </li>",
"    <li>",
"     Correlagen Diagnostics: www.correlagen.com (Accessed on June 02, 2011).",
"    </li>",
"    <li>",
"     In the United States, Children's Hospitals with expertise in diagnostic testing for primary immunodeficiencies include Cincinnati Children's Hospital Medical Center (www.cincinnatichildrens.org), Children's Hospital of Wisconsin in Milwaukee (www.chw.org) and Seattle Children's Hospital (www.seattlechildrens.org).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/5\">",
"      Oliveira JB, Fleisher TA. Laboratory evaluation of primary immunodeficiencies. J Allergy Clin Immunol 2010; 125:S297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/6\">",
"      Oliveira JB, Fleisher TA. Molecular- and flow cytometry-based diagnosis of primary immunodeficiency disorders. Curr Allergy Asthma Rep 2010; 10:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/7\">",
"      Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev 2009; 22:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/8\">",
"      Tu W, Chen S, Sharp M, et al. Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol 2004; 172:3260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/9\">",
"      Comans-Bitter WM, de Groot R, van den Beemd R, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 1997; 130:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/10\">",
"      Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003; 112:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/11\">",
"      Laurence J. T-cell subsets in health, infectious disease, and idiopathic CD4+ T lymphocytopenia. Ann Intern Med 1993; 119:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/12\">",
"      Kalman L, Lindegren ML, Kobrynski L, et al. Mutations in genes required for T-cell development: IL7R, CD45, IL2RG, JAK3, RAG1, RAG2, ARTEMIS, and ADA and severe combined immunodeficiency: HuGE review. Genet Med 2004; 6:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/13\">",
"      Yates AB, deShazo RD. Delayed hypersensitivity skin testing. Immunol Allergy Clin North Am 2001; 21:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/14\">",
"      Franz ML, Carella JA, Galant SP. Cutaneous delayed hypersensitivity in a healthy pediatric population: diagnostic value of diptheria-tetanus toxoids. J Pediatr 1976; 88:975.",
"     </a>",
"    </li>",
"    <li>",
"     Bonilla FA. Combined B- and T-cell deficiencies. In: Manual of clinical laboratory immunology, 6th ed, Detrick, B, Hamilton, RG, Rose, NR (Eds), ASM Press, Washington, DC 2002. p.819.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/16\">",
"      Moris A, Teichgr&auml;ber V, Gauthier L, et al. Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection. J Immunol 2001; 166:4818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/17\">",
"      Bonilla FA. Interpretation of lymphocyte proliferation tests. Ann Allergy Asthma Immunol 2008; 101:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/18\">",
"      Chiang JL, Patterson R, McGillen JJ, et al. Long-term corticosteroid effect on lymphocyte and polymorphonuclear cell function in asthmatics. J Allergy Clin Immunol 1980; 65:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/19\">",
"      Hicks MJ, Jones JF, Thies AC, et al. Age-related changes in mitogen-induced lymphocyte function from birth to old age. Am J Clin Pathol 1983; 80:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/20\">",
"      Nisbet-Brown ER, Lee JW, Cheung RK, Gelfand EW. Antigen-specific and -nonspecific mitogenic signals in the activation of human T cell clones. J Immunol 1987; 138:3713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/21\">",
"      Molina IJ, Sancho J, Terhorst C, et al. T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. J Immunol 1993; 151:4383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/22\">",
"      Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997; 130:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/23\">",
"      Rinaldo CR Jr. Immune suppression by herpesviruses. Annu Rev Med 1990; 41:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/24\">",
"      Stone KD, Feldman HA, Huisman C, et al. Analysis of in vitro lymphocyte proliferation as a screening tool for cellular immunodeficiency. Clin Immunol 2009; 131:41.",
"     </a>",
"    </li>",
"    <li>",
"     The Complement Laboratory of the National Jewish Mecial Center, Denver, CO.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/58/43945/abstract/26\">",
"      Netea MG, van de Veerdonk FL, van Deuren M, van der Meer JW. Defects of pattern recognition: primary immunodeficiencies of the innate immune system. Curr Opin Pharmacol 2011; 11:412.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3903 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-49CB555465-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43945=[""].join("\n");
var outline_f42_58_43945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H674024\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19688153\">",
"      INITIAL APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3063312\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22450775\">",
"      Initial screening laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22450812\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7642616\">",
"      CATEGORIES AND PREVALENCE OF IMMUNE DEFICIENCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22451541\">",
"      OVERVIEW OF CLINICAL MANIFESTATIONS AND TESTING FOR SPECIFIC COMPONENTS OF THE IMMUNE SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17005404\">",
"      Antibody deficiency and defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19688885\">",
"      - Measurement of antibody levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19688892\">",
"      - Measurement of antibody function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H183845940\">",
"      Measurement of immune globulin loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Defects in cellular immunity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Complete blood count with differential and blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H674032\">",
"      Evaluation of lymphopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14668033\">",
"      - Cutaneous delayed-type hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14668060\">",
"      Method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Flow cytometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3063384\">",
"      Abnormalities in immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4354648\">",
"      - Advanced tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - In vitro studies of T cell function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Response to mitogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Response to specific antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5551356\">",
"      Neutrophil defects (defects in phagocyte function)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1470308\">",
"      - Evaluation of neutrophil numbers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14668477\">",
"      - Evaluation of neutrophil function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5551391\">",
"      Complement defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4354744\">",
"      Innate immune defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4354757\">",
"      - Natural killer cell defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H137261\">",
"      - Defects of IL-12/23-IFN-gamma pathways",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4354769\">",
"      - Toll-like receptor pathway defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H674024\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3903\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3903|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/56/29571\" title=\"diagnostic image 1\">",
"      Chest x-rays with and without thymic shadows",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3903|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/52/26436\" title=\"picture 1\">",
"      CHS smear giant granules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/13/8400\" title=\"picture 2\">",
"      SGD neutrophil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3903|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/2/8236\" title=\"table 1\">",
"      Causes of lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/10/31915\" title=\"table 2\">",
"      Lymphocyte markers by cytometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/4/33869\" title=\"table 3\">",
"      Lymphocytes in immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29542?source=related_link\">",
"      Acquired disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16986?source=related_link\">",
"      An overview of the innate immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43433?source=related_link\">",
"      Approach to the adult with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28329?source=related_link\">",
"      CD3/T cell receptor complex disorders causing immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42278?source=related_link\">",
"      Chediak-Higashi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10826?source=related_link\">",
"      Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/45/38617?source=related_link\">",
"      Common variable immunodeficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/12/22729?source=related_link\">",
"      DiGeorge syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=related_link\">",
"      Flow cytometry for the diagnosis of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32153?source=related_link\">",
"      Hyperimmunoglobulin E syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13258?source=related_link\">",
"      IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24614?source=related_link\">",
"      Laboratory evaluation of neutropenia and neutrophil dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22953?source=related_link\">",
"      Leukocyte adhesion deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/14/19690?source=related_link\">",
"      Mannose-binding lectin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=related_link\">",
"      Mendelian susceptibility to mycobacterial diseases (MSMD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30889?source=related_link\">",
"      NK cell deficiency syndromes: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10838?source=related_link\">",
"      Neutrophil-specific granule deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24570?source=related_link\">",
"      Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17209?source=related_link\">",
"      Selective antibody deficiency with normal immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/36/41544?source=related_link\">",
"      Transient hypogammaglobulinemia of infancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_58_43946="Vascular structures 1";
var content_f42_58_43946=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79290%7EDERM%2F56826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=35\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79290%7EDERM%2F56826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=35\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 642px\">",
"   <div class=\"ttl\">",
"    Vascular structures most commonly seen in melanocytic tumors",
"    <sup>",
"     [1-3]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 622px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors. J Am Acad Dermatol 2010; 63:377.",
"       </li>",
"       <li>",
"        Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part I. Melanocytic skin tumors. J Am Acad Dermatol 2010; 63:361.",
"       </li>",
"       <li>",
"        Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol 2004; 140:1485",
"       </li>",
"       <li>",
"        Ka VS, Clark-Loeser L, Marghoob AA. Vascular pattern in seborrheic keratoses and melanoma. Dermatol Surg 2004; 30:75.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 692px\">",
"   <div class=\"ttl\">",
"    Vascular structures most commonly seen in nonmelanocytic tumors",
"    <sup>",
"     [1-3]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 672px; height: 723px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The presence of a given vessel morphology is not exclusive to a particular diagnosis. For example, arborizing vessels are commonly seen in basal cell carcinoma but they can also be seen in melanoma and intradermal nevi. Another example would be that although hairpin vessels are commonly associated with seborrheic keratoses, they can also be seen in melanoma. With that said, this table highlights vessels that are most commonly associated with non-melanocytic tumors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors. J Am Acad Dermatol 2010; 63:377.",
"       </li>",
"       <li>",
"        Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part I. Melanocytic skin tumors. J Am Acad Dermatol 2010; 63:361.",
"       </li>",
"       <li>",
"        Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol 2004; 140:1485.",
"       </li>",
"       <li>",
"        Pan Y, Chamberlain AJ, Bailey M, et al. Dermatoscopy aids in the diagnosis of the solitary red scaly patch or plaque-features distinguishing superficial basal cell carcinoma, intraepidermal carcinoma, and psoriasis. J Am Acad Dermatol 2008; 59:268.",
"       </li>",
"       <li>",
"        Braun RP, Rabinovitz HS, Krischer J, et al. Dermoscopy of pigmented seborrheic keratosis: a morphological study. Arch Dermatol 2002; 138:1556.",
"       </li>",
"       <li>",
"        Ka VS, Clark-Loeser L, Marghoob AA. Vascular pattern in seborrheic keratoses and melanoma. Dermatol Surg 2004; 30:75.",
"       </li>",
"       <li>",
"        Altamura D, Menzies SW, Argenziano G, et al. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol 2010; 62:67.",
"       </li>",
"       <li>",
"        Zalaudek I, Giacomel J, Argenziano G, et al. Dermoscopy of facial nonpigmented actinic keratosis. Br J Dermatol 2006; 155:951.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43946=[""].join("\n");
var outline_f42_58_43946=null;
var title_f42_58_43947="Diagnosis of hepatitis D";
var content_f42_58_43947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnosis of hepatitis D virus infection in different clinical settings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnostic markers",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acute HBV/HDV coinfection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acute HDV superinfection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chronic HDV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-HBc, IgM",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum HDAg (by EIA/RIA)",
"       </td>",
"       <td>",
"        Early and short-lived, frequently missed",
"       </td>",
"       <td>",
"        Early and transient, and frequently missed",
"       </td>",
"       <td>",
"        Not detectable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum HDV RNA (by hybridization)",
"       </td>",
"       <td>",
"        Early, transient but last longer than HDAg",
"       </td>",
"       <td>",
"        Early and persistent",
"       </td>",
"       <td>",
"        Usually positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-HDV, total",
"       </td>",
"       <td>",
"        Late, low titer",
"       </td>",
"       <td>",
"        Rapidly increasing titers",
"       </td>",
"       <td>",
"        High titers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-HDV, IgM",
"       </td>",
"       <td>",
"        Transient, may be the only marker",
"       </td>",
"       <td>",
"        Rapidly increasing and persistent titers",
"       </td>",
"       <td>",
"        Variable titers, usually high",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver HDAg",
"       </td>",
"       <td>",
"        Not indicated",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td>",
"        Usually positive, may be negative in late stages",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43947=[""].join("\n");
var outline_f42_58_43947=null;
var title_f42_58_43948="Pathogenesis of bronchiolitis";
var content_f42_58_43948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathogenesis of bronchiolitis obliterans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 255px; height: 222px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the steps involved in the pathogenesis of bronchiolitis obliterans. An initial insult to the bronchial epithelium eventually leads to either fibrosis or resolution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43948=[""].join("\n");
var outline_f42_58_43948=null;
var title_f42_58_43949="Features distinguishing dissociative PTSD from other disorders";
var content_f42_58_43949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F65750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F65750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features that typically distinguish the dissociative subtype of PTSD from borderline personality disorder, bipolar disorder and schizophrenia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dissociative subtype PTSD",
"       </td>",
"       <td class=\"subtitle1\">",
"        Schizophrenia and psychotic disorders",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bipolar disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Borderline personality disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Trauma",
"        </strong>",
"       </td>",
"       <td>",
"        Typically report early onset, severe, chronic childhood trauma.",
"       </td>",
"       <td>",
"        Less likely to have severe, chronic childhood trauma.",
"       </td>",
"       <td>",
"        Less likely to have severe, chronic childhood trauma.",
"       </td>",
"       <td>",
"        Although may report a history of childhood trauma, it may be less severe or chronic than with dissociative disorders.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Dissociative symptoms",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Typically endorse high levels (eg, DES average score high 20s or more) with intact reality testing.",
"        </p>",
"        <p>",
"         Often prefer to feel numb than to have strong feelings. May self-harm to induce a state of dissociation from traumatic experiences.",
"        </p>",
"       </td>",
"       <td>",
"        Endorse mildly high symptoms (eg, DES average score 17.6) with poor reality testing.",
"       </td>",
"       <td>",
"        Lower dissociation scores expected.",
"       </td>",
"       <td>",
"        <p>",
"         Moderate symptoms (eg, DES average in the low 20s) but significantly lower than DID with intact reality testing; may not be different from dPTSD on derealization and depersonalization, but usually lower on amnesia.",
"        </p>",
"        <p>",
"         Often find it distressing to feel numb and may self-harm to end an episode of dissociation.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Hallucinatory experiences",
"        </strong>",
"       </td>",
"       <td>",
"        In severe cases, may endorse hearing voice(s) but aware of the \"as if\" quality (\"I know they're not real but I hear a child crying as she gets yelled at\"); may experience brief periods of \"seeing\" past traumatic events in flashback; reality testing otherwise intact; auditory and visual hallucinations relate to high dissociativity/hypnotizability.",
"       </td>",
"       <td>",
"        May endorse voices without awareness of the hallucinatory quality; may have visual hallucinations without recognition they are not real; hallucinations are due to psychotic process.",
"       </td>",
"       <td>",
"        Experiences hallucinations only during episodes of psychotic mania- or depression; in psychotic depression, any voices are typically solely persecutory.",
"       </td>",
"       <td>",
"        If experiences hallucinatory experiences, they are brief, distressing and occur during stress; if endorses voices, they express patient's polarized thoughts.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Affect",
"        </strong>",
"       </td>",
"       <td>",
"        Typically experience a range of affective states including numbed and detached; severe cases may have inexplicable, rapid mood changes that may be triggered by internal or external precipitants (eg, sad to angry to helpless and afraid). Many mood shifts can occur per day; rarely complain of \"emptiness\".",
"       </td>",
"       <td>",
"        Flat and/or inappropriate affect.",
"       </td>",
"       <td>",
"        Shifts in mood state occur more slowly (take at least 12 hours to shift mood state and usually much longer than that).",
"       </td>",
"       <td>",
"        Affect is typically less modulated than in dPTSD and shifts according to external precipitants; often the most frequent affects are emptiness and intense anger.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ability to perceive accurately and think logically",
"        </strong>",
"       </td>",
"       <td>",
"        Perceptions are generally accurate; thinking is usually logical and organized except for brief periods following traumatic intrusions or periods of intense flooding of traumatic symptoms.",
"       </td>",
"       <td>",
"        Perception may be less accurate than in dPTSD; thinking tends to be less logical and organized.",
"       </td>",
"       <td>",
"        Disturbed only during mood episodes.",
"       </td>",
"       <td>",
"        Perception tends to be distorted and thinking is less logical, particularly when stressed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Working alliance",
"        </strong>",
"       </td>",
"       <td>",
"        Generally capable of developing a working alliance with therapist; interested in others despite fear of being hurt; usually capable of self-reflection; may have long-standing relationships and/or be avoidant and prefer to be alone because it feels \"safer\".",
"       </td>",
"       <td>",
"        Less capable of developing a working alliance; generally less interested in others; less capacity for self-reflection.",
"       </td>",
"       <td>",
"        Capable of developing a working alliance.",
"       </td>",
"       <td>",
"        Often less capable of developing a working alliance; pattern of overvaluing/devaluing therapist, provocations and fear of abandonment; may expect others to be less cooperative than dPTSD; often have about the same level of interest in others as in DID; less capacity for self-reflection than in DID; history of tumultuous, chaotic relationships and difficulty tolerating being alone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Comorbidity",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Usually meet criteria for multiple comorbid disorders including mood disorders, PTSD and other anxiety disorders, substance disorders, mixed personality disorders, somatoform disorders as well as multiple medical illnesses such as headaches, fibromyalgia, gastrointestinal, and gynecological problems.",
"        </p>",
"        <p>",
"         Usually meet BPD criteria when severely decompensated/having overwhelming PTSD/dissociative disorder symptoms; most do not meet BPD criteria once stabilized.",
"        </p>",
"       </td>",
"       <td>",
"        Typically meet criteria for fewer comorbid conditions although substance disorders are common.",
"       </td>",
"       <td>",
"        Typically meet criteria for fewer comorbid conditions, but comorbid substance abuse is common.",
"       </td>",
"       <td>",
"        Often have a variety of comorbid disorders, but less prevalence of PTSD, somatoform disorders.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DES: Dissociative Experiences Scale; DID: dissociative identitiy disorder; dPTSD: dissociative subtype of PTSD; PTSD: posttraumatic stress disorder; BPD: borderline personality disorder.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Brand B, Loewenstein RJ. Dissociative disorders: an overview of assessment, phenomenology and treatment. Psychiatric Times 2010.",
"       </li>",
"       <li>",
"        Brand BL, Armstrong JG, Loewenstein RJ, McNary SW. Personality differences on the Rorschach of dissociative identity disorder, borderline personality disorder and psychotic inpatients. Psychol Trauma 2009; 1:188.",
"       </li>",
"       <li>",
"        Briere J, Weathers FW, Runtz M. Is dissociation a multidimensional construct? Data from the Multiscale Dissociation Inventory. J Traumatic Stress 2005; 18:221.",
"       </li>",
"       <li>",
"        Boon S, Draijer N. The differentiation of patients with MPD or DDNOS from patients with a Cluster B personality disorder. Dissociation 1993; 6:126.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43949=[""].join("\n");
var outline_f42_58_43949=null;
var title_f42_58_43950="Contents: Adult signs and symptoms";
var content_f42_58_43950=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adult signs and symptoms",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult signs and symptoms",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute and emergent",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/4/35912\">",
"           Acute urinary retention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38391\">",
"           An overview of angioedema: Pathogenesis and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/45/35541\">",
"           Approach to dermatologic diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/52/9034\">",
"           Approach to the adult patient with syncope in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/17/32025\">",
"           Approach to the adult with acute diarrhea in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/11/31927\">",
"           Approach to the adult with fever of unknown origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/47/16120\">",
"           Approach to the adult with nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/43/23223\">",
"           Approach to the patient with dizziness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/27/20920\">",
"           Approach to vaginal bleeding in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/22/25962\">",
"           Assessment and management of the acutely agitated or violent adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/4/15431\">",
"           Etiologies of fever of unknown origin in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/24/14727\">",
"           Etiology and evaluation of hemoptysis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/32/34311\">",
"           Evaluation of abnormal behavior in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/39/20090\">",
"           Evaluation of chest pain in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/50/41770\">",
"           Evaluation of the adult with abdominal pain in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/58/27562\">",
"           Evaluation of the adult with acute weakness in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/16/28938\">",
"           Evaluation of the adult with dyspnea in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/49/39704\">",
"           Evaluation of the adult with headache in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/52/40778\">",
"           Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ambulatory",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38391\">",
"           An overview of angioedema: Pathogenesis and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/45/35541\">",
"           Approach to dermatologic diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/63/8184\">",
"           Approach to minimal bright red bleeding per rectum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/36/23111\">",
"           Approach to the adult patient with fatigue",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/17/32025\">",
"           Approach to the adult with acute diarrhea in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/41/1690\">",
"           Approach to the adult with epistaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/11/31927\">",
"           Approach to the adult with fever of unknown origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/47/16120\">",
"           Approach to the adult with nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/10/18601\">",
"           Approach to the diagnosis and evaluation of low back pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/43/23223\">",
"           Approach to the patient with dizziness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/4/27720\">",
"           Approach to the patient with dyspepsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/4/26694\">",
"           Approach to the patient with muscle weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/14/17641\">",
"           Approach to the patient with night sweats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/8/31879\">",
"           Approach to the patient with sensory loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/19/32057\">",
"           Approach to the patient with vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/57/7065\">",
"           Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/36/34375\">",
"           Clinical manifestations and diagnosis of edema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/59/16312\">",
"           Definition and pathogenesis of chronic pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/30/16874\">",
"           Differential diagnosis of abdominal pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/0/26634\">",
"           Differential diagnosis of chest pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/4/15431\">",
"           Etiologies of fever of unknown origin in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/22/40296\">",
"           Evaluation of chronic pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/17/12569\">",
"           Evaluation of dysphagia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/51/5942\">",
"           Evaluation of nonacute scrotal pathology in adult men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/18/5418\">",
"           Evaluation of subacute and chronic cough in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/15/18682\">",
"           Evaluation of syncope in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/20/44360\">",
"           Evaluation of the acute scrotum in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/14/28904\">",
"           Evaluation of the adult with monoarticular pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/15/34039\">",
"           Evaluation of the adult with polyarticular pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/12/17607\">",
"           Evaluation of the red eye",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/34/3624\">",
"           Headache syndromes other than migraine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/24/29060\">",
"           Muscle examination in the evaluation of weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/41/21146\">",
"           Overview of cancer pain syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/36/22087\">",
"           Overview of hiccups",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/11/20665\">",
"           Overview of palpitations in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/60/39879\">",
"           Primary dysmenorrhea in adult women: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/54/10090\">",
"           Pruritus: Etiology and patient evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/58/6058\">",
"           Pruritus: Overview of management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/62/13290\">",
"           Treatment of insomnia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/52/40778\">",
"           Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/36/28233\">",
"           Treatment of primary dysmenorrhea in adult women",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-E34F0B4620-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f42_58_43950=[""].join("\n");
var outline_f42_58_43950=null;
var title_f42_58_43951="Clubbing of the fingers";
var content_f42_58_43951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clubbing of the fingers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a normal finger, the length of the perpendicular dropped from point A to point B should be greater than a similar line from C to D. In clubbing, the relationships are reversed - that is, the distance C-D is greater than the distance A-B. The other important change is the angle described by A-C-E. In the normal finger this is usually &lt;180 degrees whereas in clubbing it is &gt;180 degrees.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from DeRemee RA. Facets of the algorithmic synthesis. In: DeRemee RA, (Ed), Clinical profiles of diffuse interstitial pulmonary disease, Mount Kisco, NY, Futura Publishing Company, Inc, 1990, pp. 9-44.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_58_43951=[""].join("\n");
var outline_f42_58_43951=null;
